875open events
525results logged
215results, 30 days
9619source documents
573symbols
deepseek-flashagent model
Upcoming events
Open expectations. Dates are the expected window, not a forecast by this site.
| Expected window | Imminence▲ | Symbol | Drug | Event | Tier | LLM predict | Source | Notes |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 → 2026-09-30 overdue | -36d | ATOSAtossa Therapeutics | (Z)-endoxifen small molecule · womens health | topline_results | Watch | — | document | 10-Q (Aug 7, 2026), Karisma-(Z)-endoxifen Ph2 MBD study 24-month follow-up mammographic review: "We expect to report top-line durability data from the Karisma-(Z)-endoxifen study in the third quarter of 2026" (also "expected to be received before the end of the third quarter of 2026"). Window per Q3 2026 = 2026-07-01..2026-09-30; no result disclosed in documents to date. Resolution checked 2026-11-03: no outcome found. |
| 2026-10-28 overdue | -8d | SLSSELLAS Life Sciences Group | galinpepimut-S peptide · hematology | interim_analysis | Core | — | document | Oct 28, 2026 GlobeNewswire: Phase 3 REGAL (AML) "reached its pre-specified 80th event, triggering the final analysis" — a pre-specified data-cutoff/milestone announcement, not data itself; "Company to Report Topline Primary Endpoint Results this Quarter" (tracked in event 1083). Checked 2026-11-04: still no topline/results disclosed. |
| 2026-10-01 → 2026-10-31 overdue | -5d | IVVDInvivyd | VYD2311 monoclonal antibody · infectious | topline_results | Core | large impact 50% confidence | document | "DECLARATION topline data on safety and immunogenicity to support the submission are now expected in October". Slipped from prior guidance of late Q3 2026. Blinded clinical efficacy events to be unblinded post-Accelerated Approval, no date given. Resolution checked 2026-11-01: no outcome found. October 2026 documents (10/01, 10/04) are recaps of the 2026-09-29 LIBERTY topline release and give no DECLARATION data. |
| 2026-11-01 → 2026-11-30 open | 25d | DWTXDogwood Therapeutics | Halneuron small molecule · pain anesthesia | topline_results | Core | large impact 80% confidence | document | "advance the ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain (CINP) trial toward topline data readout in November 2026"; earlier 8-K (2026-08-13) guided only "fall of 2026" - narrowed to November 2026 per the later filing. 217/220+ patients enrolled. |
| 2026-11-01 → 2026-11-30 open | 25d | IBRXImmunityBio | ANKTIVA protein · oncology | topline_results | Core | large impact 45% confidence | document | "ImmunityBio announced completion of the database lock for Cohort A of the registrational QUILT-2.005 trial in BCG-naive NMIBC (company release 2026-10-21); topline results expected in November 2026 per "ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears". Month only, so window covers November 2026. |
| 2026-11-01 → 2026-11-30 open | 25d | PEPGPepGen | PGN-EDODM1 aso · cns | topline_results | Core | large impact 60% confidence | document | "10 mg/kg FREEDOM2-DM1 cohort fully enrolled, with 7 of 8 participants having completed dosing; data expected in November" (10-Q: "we expect to report data from this cohort in November, 2026"). |
| 2026-11-01 → 2026-11-30 open | 25d | PHARPharming Group | leniolisib small molecule · immunology | topline_results | Core | small impact 72% confidence | document | "Pharming expects topline Phase II results from its separate trial in CVID patients with immune dysregulation ... in November 2026" (narrowed from prior Q4 2026 guidance). |
| 2026-11-01 → 2026-11-30 open | 25d | SLGLSol-Gel Technologies | SGT-610 (patidegib gel, 2%) small molecule · oncology | topline_results | Core | large impact 80% confidence | document | Q2 2026 release: "Last patient last visit is expected in September 2026, and top-line results are scheduled for late November 2026." Reaffirmed in 2026-09-17 6-K after LPLV ("Top-line results remain on track for late November 2026"). Pivotal Phase 3 (SGT-610-01) in Gorlin syndrome; no day-level date given. |
| 2026-11-01 → 2026-11-30 open | 25d | VANIVivani Medical | NPM-139 peptide · metabolic | topline_results | Core | large impact 55% confidence | document | "Top-line data from the 20-participant trial is expected in November of 2026" (SLIM-1 Phase 1, NPM-139 semaglutide implant vs Wegovy). Month given only; restated in the Aug 13, 2026 business update and 10-Q. |
| 2026-09-22 → 2026-12-21 open | 46d | ANNXAnnexon | ANX1502 small molecule · hematology | topline_results | Watch | small impact 80% confidence | document | "POC Data for ANX1502 ... Expected in Fall 2026" (Q2 2026 release, 2026-08-12); 10-Q: "Dosing is complete and we plan to provide an update on the POC study in the second half of 2026." Window covers Fall 2026 (2026-09-22..2026-12-21). |
| 2026-10-01 → 2026-12-31 open | 56d | ABCLAbCellera Biologics | ABCL575 monoclonal antibody · immunology | topline_results | Watch | small impact 88% confidence | document | 10-Q (Aug 5, 2026): "Dosing for the Phase 1 study has been completed with the top-line data readout expected in Q4 2026" for ABCL575. Company states no plans to pursue development past Phase 1. |
| 2026-07-01 → 2026-12-31 open | 56d | ABSIAbsci | ABS-201 monoclonal antibody · dermatology | interim_analysis | Watch | large impact 60% confidence | document | "Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026" (MAD portion of HEADLINE Phase 1/2a in pattern hair loss). |
| 2026-11-04 → 2026-12-31 open | 56d | ACIUAC Immune | ACI-7104 vaccine · cns | interim_analysis | Watch | small impact 72% confidence | document | "Data will be available before year-end on the characterization of ACI-7104-induced antibodies including their a-syn binding properties"; additional clinical data from VacSYn Part 1 expected before year-end. Window from release date to 2026-12-31. |
| 2026-10-01 → 2026-12-31 open | 56d | ACRSAclaris Therapeutics | bosakitug (ATI-045) monoclonal antibody · dermatology | topline_results | Watch | small impact 50% confidence | document | "Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug Expected in the Fourth Quarter 2026"; 109-patient ADMIRATION trial fully enrolled; CEO: "Phase 2 results in AD from bosakitug ... in the coming few weeks" (no specific date stated). Timeline reaffirmed 2026-11-05. |
| 2026-07-01 → 2026-12-31 open | 56d | ACRVAcrivon Therapeutics | ACR-368 small molecule · oncology | interim_analysis | Watch | large impact 55% confidence | document | "A prespecified simultaneous interim analysis and data update from both all-comer (biopsy-independent) serous EC arms of the ACR-368 Phase 2b study in second half of 2026" (8-K Ex-99.1; same wording in 10-Q). Window per "second half of 2026". |
| 2026-07-01 → 2026-12-31 open | 56d | AGIOAgios Pharmaceuticals | AG-181 small molecule · rare genetic | topline_results | Watch | small impact 80% confidence | document | 8-K: "Agios dosed the first patient in the Phase 1b trial evaluating the safety and tolerability of AG-181 in adults with PKU. Data from this trial are expected in the second half of 2026." 10-Q: expect to "confirm proof of mechanism in the second half of 2026" (PKU, PAH stabilizer). |
| 2026-11-01 → 2026-12-31 open | 56d | ALKSAlkermes | alixorexton small molecule · cns | topline_results | Watch | small impact 68% confidence | document | Q2 2026 release: "topline results from our alixorexton phase 2 idiopathic hypersomnia study expected toward year-end" (Vibrance-3). Window interpreted as late 2026. |
| 2026-11-01 → 2026-12-31 open | 56d | ALLOAllogene Therapeutics | ALLO-329 cell therapy · immunology | interim_analysis | Watch | large impact 50% confidence | document | "Dose escalation and lymphodepletion optimization are ongoing, and we expect to provide a clinical and translational data update in late 2026." (RESOLUTION Phase 1, SLE/IIM/SSc); window per "late 2026". |
| 2026-07-01 → 2026-12-31 open | 56d | ALXOALX Oncology Holdings | ALX2004 adc · oncology | interim_analysis | Watch | small impact 55% confidence | document | "Enrollment continues in the dose-escalation portion of the Phase 1 trial of ALX2004 ... on track to report safety data in the second half of 2026"; 2H 2026=2026-07-01..2026-12-31 |
| 2026-07-01 → 2026-12-31 open | 56d | ANNXAnnexon | tanruprubart monoclonal antibody · immunology | interim_analysis | Watch | small impact 55% confidence | document | 10-Q: "we anticipate initial PK, PD, biomarker and functional data in the second half of 2026 to supplement our comprehensive data package for tanruprubart in GBS" from the ongoing open-label U.S./Europe FORWARD study; data to precede FDA engagement and Q4 2026 BLA submission. Distinct from the Aug 2026 initial-cohort (n=10) clinical response results. |
| 2026-10-01 → 2026-12-31 open | 56d | ANNXAnnexon | vonaprument monoclonal antibody · ophthalmology | topline_results | Watch | large impact 72% confidence | document | "The Month 15 primary endpoint remains on track for the fourth quarter of 2026" (10-Q, 2026-08-12); reiterated in the 2026-10-28 investor-event release ("anticipated 15-month and 24-month results beginning in Q4 2026") and the 2026-11-04 recap. Guidance only - no data disclosed as of 2026-11-04; full Q4 2026 window. |
| 2026-10-01 → 2026-12-31 open | 56d | ARQTArcutis Biotherapeutics | ZORYVE (roflumilast) foam 0.3% small molecule · dermatology | topline_results | Watch | small impact 78% confidence | document | Phase 2 proof-of-concept vitiligo study enrollment complete; "expects to report results, as well as decisions on program advancement ... in the fourth quarter of 2026". |
| 2026-07-01 → 2026-12-31 open | 56d | ATOSAtossa Therapeutics | (Z)-endoxifen small molecule · oncology | interim_analysis | Watch | small impact 55% confidence | document | 10-Q (Aug 7, 2026): I-SPY2 EOP expanded combination arms ((Z)-endoxifen + abemaciclib or elagolix): "Enrollment for all arms of this expanded study using (Z)-endoxifen as a combination therapy is complete, and we expect to begin receiving data throughout the second half of 2026." Window per 2H26 = 2026-07-01..2026-12-31; data timing only, not stated as topline. |
| 2026-10-01 → 2026-12-31 open | 56d | ATOSAtossa Therapeutics | (Z)-endoxifen small molecule · oncology | topline_results | Watch | small impact 45% confidence | document | EVANGELINE Phase 2 (neoadjuvant, premenopausal ER+/HER2- breast cancer): "Enrollment completed, top line data anticipated in 4Q26". Slide also notes final Ph2 data anticipated in 1H27; 4Q26 is the first/topline readout. |
| 2026-10-01 → 2026-12-31 open | 56d | BBOTBridgeBio Oncology Therapeutics | BBO-11818 small molecule · oncology | topline_results | Watch | large impact 45% confidence | document | "BBO-11818 and BBO-10203 monotherapy data update in the fourth quarter of 2026." Q4 as defined = Oct 1-Dec 31, 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | BBOTBridgeBio Oncology Therapeutics | BBO-10203 small molecule · oncology | topline_results | Watch | large impact 45% confidence | document | "BBO-11818 and BBO-10203 monotherapy data update in the fourth quarter of 2026." Q4 as defined = Oct 1-Dec 31, 2026. |
| 2026-08-05 → 2026-12-31 open | 56d | BCRXBioCryst Pharmaceuticals | BCX17725 protein · dermatology | topline_results | Watch | small impact 80% confidence | document | "expects to report data from this part by the end of 2026"; Phase 1 Part 4 in Netherton syndrome, up to 12 patients. Window starts at the Aug 5, 2026 disclosure date. |
| 2026-10-01 → 2026-12-31 open | 56d | BDTXBlack Diamond Therapeutics | silevertinib small molecule · oncology | interim_analysis | Watch | large impact 40% confidence | document | "The Company plans to provide an update on the Phase 2 trial of silevertinib in frontline patients with non-classical EGFR-mutant (EGFRm) NSCLC in the fourth quarter of 2026." Q4 2026 guidance; prior cut was ASCO 2026 (Apr 11, 2026 data cutoff). |
| 2026-08-04 → 2026-12-31 open | 56d | BEAMBeam Therapeutics | risto-cel cell therapy · hematology | topline_results | Watch | small impact 75% confidence | document | "Beam expects to report updated clinical data by year-end 2026 and submit a U.S. BLA for risto-cel as early as year-end 2026" (Q3 2026 release, 2026-11-03; same guidance as 2026-08-04 10-Q; BEACON dosing complete in all adult and adolescent patients). Window = document date..2026-12-31. |
| 2026-07-01 → 2026-12-31 open | 56d | BHVNBiohaven | BHV-7000 small molecule · cns | topline_results | Watch | small impact 45% confidence | document | "No impact to RISE 3 timelines. The study is fully enrolled and randomized, dosing is ongoing, and topline data remains on track for the second half of 2026" (2H 2026 = 2026-07-01..2026-12-31). Reaffirmed in Q3 2026 release/10-Q on 2026-10-29 despite Sept 4, 2026 partial clinical hold on new enrollment. |
| 2026-07-01 → 2026-12-31 open | 56d | BIOABioAge Labs | BGE-102 small molecule · metabolic | topline_results | Watch | large impact 50% confidence | document | Q2 2026 release: QUELL-CV Phase 2 (oral BGE-102, NLRP3 inhibitor) in obesity with elevated inflammation/CV risk; "topline data anticipated in the second half of 2026". |
| 2026-07-01 → 2026-12-31 open | 56d | CHRSCoherus Oncology | casdozokitug monoclonal antibody · oncology | topline_results | Watch | large impact 50% confidence | document | "Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected 2H 2026." Release also projects public disclosure of data sets with sufficient maturity in early October 2026. |
| 2026-11-01 → 2026-12-31 open | 56d | CLDXCelldex Therapeutics | barzolvolimab monoclonal antibody · dermatology | topline_results | Watch | small impact 55% confidence | document | Phase 2 atopic dermatitis study: "Topline data from this study are expected to be presented in late 2026." Window = late 2026 (2026-11-01 to 2026-12-31). |
| 2026-10-01 → 2026-12-31 open | 56d | CLYMClimb Bio | budoprutug monoclonal antibody · immunology | topline_results | Watch | small impact 60% confidence | document | Guided budoprutug Q4 2026 readouts: ITP "additional data from the 500 mg and 1000 mg cohorts in the fourth quarter of 2026" and SLE "data, including safety and biomarker data from the Global study in the fourth quarter of 2026." Window = Q4 2026 (2026-10-01..2026-12-31). Neither reported as of 2026-10-26. | ITP data now guided to ASH 2026 poster #3003 on 2026-12-13 (event 1206); SLE Global study data still expected Q4 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | CMPXCompass Therapeutics | CTX-8371 bispecific · oncology | interim_analysis | Watch | small impact 60% confidence | document | "Additional data from the cohort expansions are expected in Q4 2026" (PD-1 x PD-L1 Phase 1 expansions in TNBC, NSCLC, HL). |
| 2026-10-01 → 2026-12-31 open | 56d | CMPXCompass Therapeutics | CTX-10726 bispecific · oncology | interim_analysis | Watch | small impact 60% confidence | document | "initial clinical data expected in Q4 2026" from the Phase 1 dose-escalation study of CTX-10726 (PD-1 x VEGF-A). |
| 2026-08-10 → 2026-12-31 open | 56d | COGTCogent Biosciences | bezuclastinib small molecule · hematology | interim_analysis | Watch | small impact 70% confidence | document | "Announced completion of enrollment in the 'avapritinib switch' SUMMIT extension trial with preliminary results expected by end of 2026." Window starts at the Aug 10, 2026 release date; enrollment completion alone is not a readout. |
| 2026-07-01 → 2026-12-31 open | 56d | CRSPCRISPR Therapeutics | CTX310 gene therapy · cardiovascular | interim_analysis | Watch | small impact 72% confidence | document | "The Company also expects to provide a Phase 1b clinical update in the second half of 2026." Window per rule: 2026-07-01..2026-12-31. |
| 2026-07-01 → 2026-12-31 open | 56d | CRSPCRISPR Therapeutics | CTX611 sirna · cardiovascular | interim_analysis | Watch | small impact 80% confidence | document | "CTX611 (SRSD107) ... is advancing through a Phase 2 clinical trial in patients undergoing total knee arthroplasty (TKA). The Company expects to provide an update in the second half of 2026." Q3 2026 release (2026-11-02): enrollment now complete, "with an update expected in the second half of 2026." Window unchanged. |
| 2026-07-01 → 2026-12-31 open | 56d | CRSPCRISPR Therapeutics | zugocabtagene geleucel cell therapy · immunology | interim_analysis | Watch | small impact 70% confidence | document | Autoimmune: "Enrollment across the zugo-cel autoimmune clinical program continues ... The Company expects to provide further updates in the second half of 2026." Immuno-oncology B-cell malignancies: "updates anticipated in the second half of 2026." Both updates guided to H2 2026 (2026-07-01..2026-12-31). |
| 2026-08-06 → 2026-12-31 open | 56d | CTMXCytomX Therapeutics | varsetatug masetecan adc · oncology | interim_analysis | Watch | large impact 55% confidence | document | "A Phase 1 data update is expected by the end of 2026 with a focus on dose selection for late phase development" (monotherapy, advanced CRC; enrollment complete, 113 pts). Window per "by the end of 2026" from document date. 10-Q: "anticipated to be presented by the end of 2026". |
| 2026-12-01 → 2026-12-31 | 56d | DNTHDianthus Therapeutics | claseprubart monoclonal antibody · immunology | topline_results | Core | small impact 60% confidence | document | "top-line results with 46 patients on track for December '26" (Phase 2 MoMeNtum in MMN); enrollment completed above 36-patient target. |
| 2026-07-01 → 2026-12-31 open | 56d | DTILPrecision BioSciences | PBGENE-HBV gene therapy · infectious | interim_analysis | Watch | large impact 50% confidence | document | "The Company is targeting year-end 2026 for the next program update" for the ELIMINATE-B study in chronic hepatitis B (also 10-Q: "expect to provide additional updates on the ELIMINATE-B trial progress by the end of 2026"). |
| 2026-11-01 → 2026-12-31 open | 56d | DTILPrecision BioSciences | PBGENE-DMD gene therapy · rare genetic | interim_analysis | Watch | large impact 45% confidence | document | "Initial safety data are targeted for year-end 2026, with efficacy data at distinct timepoints expected to follow in the first and second half of 2027." (Q3 2026 10-Q, FUNCTION-DMD) Year-end 2026 = late 2026 window. |
| 2026-10-01 → 2026-12-31 open | 56d | ENGNenGene Therapeutics | detalimogene gene therapy · oncology | topline_results | Watch | large impact 45% confidence | document | "enGene expects to report updated data on key primary and secondary regulatory endpoints (CR at any time and Duration of Response (DOR) >= 12 months), as well as additional durability datapoints, from Cohort 1 ... in 4Q 2026." Landmark CR rates from pivotal cohort also guided to 4Q 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | ENTAEnanta Pharmaceuticals | EDP-978 small molecule · immunology | topline_results | Watch | small impact 68% confidence | document | "The Company expects to report topline data from the trial in the fourth quarter of 2026" (Phase 1 trial of EDP-978, oral once-daily KIT inhibitor in urticaria). 10-Q of 2026-08-12 repeats 4Q 2026 guidance. |
| 2026-12-01 → 2026-12-31 | 56d | EPRXEupraxia Pharmaceuticals | EP-104GI small molecule · gi hepatology | interim_analysis | Core | large impact 62% confidence | document | "Interim analysis of the Phase 2b portion of the study is on track for December 2026"; "we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months". Earlier guidance was Q4 2026; narrower December 2026 window stated here. Phase 2b enrollment target (120 pts) reached Oct 12, 2026. |
| 2026-07-01 → 2026-12-31 open | 56d | ERASErasca | ERAS-4001 small molecule · oncology | interim_analysis | Watch | small impact 60% confidence | document | "Preliminary Phase 1 monotherapy data expected in the second half of 2026" (BOREALIS-1, Ph1); CEO: "upcoming ERAS-4001 clinical data readout expected later this year" |
| 2026-08-13 → 2026-12-31 open | 56d | FBIOFortress Biotech | Triplex vaccine · infectious | topline_results | Watch | small impact 80% confidence | document | Q2 2026 release (Aug 13, 2026): "a potential data readout by the end of 2026 for prevention and control of CMV in patients co-infected with HIV and CMV." Window runs from the release date to year-end; company calls it "potential". |
| 2026-10-01 → 2026-12-31 open | 56d | FDMT4D Molecular Therapeutics | 4D-710 gene therapy · respiratory | interim_analysis | Watch | small impact 80% confidence | document | "AEROW Phase 1/2 clinical trial and program update expected in Q4 2026" (Q2 2026 earnings release). |
| 2026-08-04 → 2026-12-31 open | 56d | FTHFaeth Therapeutics | PIKTOR small molecule · oncology | topline_results | Watch | large impact 55% confidence | document | Phase 2 PIK-201 (endometrial cancer) topline results expected "by year-end 2026" (3Q26 release 2026-11-03: "look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end"); confirmed in 10-Q filed 2026-11-03. Window runs from Aug 2026 guidance to end of 2026. |
| 2026-08-06 → 2026-12-31 open | 56d | GLUEMonte Rosa Therapeutics | MRT-2359 small molecule · oncology | interim_analysis | Watch | small impact 80% confidence | document | "We will update data from the initial Phase 1/2 arm exploring MRT-2359 in advanced CRPC by the end of the year"; enrollment of the 6-patient AR-mutant expansion arm completed. |
| 2026-10-01 → 2026-12-31 open | 56d | HELPHelus Pharma | HLP003 small molecule · cns | topline_results | Watch | large impact 72% confidence | document | "Topline data readout from APPROACH Phase 3 study of HLP003 ... on track for Q4 2026"; reaffirmed Oct 27, 2026: "continues to anticipate reporting topline data ... in Q4 2026." Enrollment complete (223 participants); EMBRACE still enrolling. |
| 2026-07-01 → 2026-12-31 open | 56d | HOWLWerewolf Therapeutics | WTX-124 protein · oncology | interim_analysis | Watch | large impact 45% confidence | document | Q2 2026 release: "In the second half of the year, we expect to provide ... data updates on our clinical trials of WTX-124 and WTX-330." Window = 2H 2026 (broad, no specific date). 10-Q notes Phase 1/1b trial of WTX-124 expected to be completed in Q4 2026. Aug-2026 merger with Ambros adds uncertainty. |
| 2026-07-01 → 2026-12-31 open | 56d | HOWLWerewolf Therapeutics | WTX-330 protein · oncology | interim_analysis | Watch | large impact 45% confidence | document | Q2 2026 release: "In the second half of the year, we expect to provide ... data updates on our clinical trials of WTX-124 and WTX-330." Window = 2H 2026 (broad, no specific date). 10-Q: dose/regimen-determining Part A of Phase 1b/2 expected to complete Q4 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | HROWHarrow | IHEEZO small molecule · ophthalmology | topline_results | Watch | small impact 80% confidence | document | "IHEEZO (QUELL): Topline data from QUELL, a prospective, randomized, multi-center clinical trial evaluating IHEEZO in patients undergoing intravitreal injections, are expected in the fourth quarter of 2026." Q4 2026 = 2026-10-01..2026-12-31. |
| 2026-10-01 → 2026-12-31 open | 56d | HROWHarrow | NATACYN small molecule · ophthalmology | topline_results | Watch | small impact 85% confidence | document | "NATACYN: The first patients were enrolled in an investigator-initiated clinical study during the second quarter, with topline data expected in the fourth quarter of 2026." Investigator-initiated study; Q4 2026 = 2026-10-01..2026-12-31. |
| 2026-08-11 → 2026-12-31 open | 56d | IMUXImmunic | vidofludimus calcium small molecule · cns | topline_results | Watch | large impact 80% confidence | document | "top-line data from our Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis (MS) expected by year-end"/"expected to be available by the end of 2026"; window runs from document date. Twin ENSURE-1/ENSURE-2 trials, enrollment complete June 2025, 1,121 and 1,100 patients. If positive, NDA submission targeted mid-2027. Reaffirmed by CMO interview 2026-10-30 ("Phase 3 ENSURE programme in relapsing MS, with results expected by the end of 2026"). |
| 2026-08-06 → 2026-12-31 open | 56d | IMVTImmunovant | IMVT-1402 monoclonal antibody · immunology | topline_results | Watch | large impact 45% confidence | document | D2T RA Period 2 (primary endpoint at Week 28, NCT06754462): 8-K PR (2026-08-06) says the company expects to "provide further updates on its potentially registrational IMVT-1402 D2T RA program ... in the second half of calendar year 2026"; 10-Q: "Further updates on this program are expected in the second half of calendar year 2026." Guidance = 2H 2026; window starts at filing date to keep a unique key distinct from the CLE event. |
| 2026-10-01 → 2026-12-31 open | 56d | IVAInventiva S.A. American Depository Shares | lanifibranor small molecule · gi hepatology | topline_results | Watch | large impact 80% confidence | document | "Inventiva expects to report topline results from NATiV3 in the fourth quarter of 2026, as previously communicated." Phase 3 NATiV3 in MASH F2/F3; last patient completed final 72-week visit. Repeated in 2026-09-28 and 2026-10-06 releases. |
| 2026-10-15 → 2026-12-31 open | 56d | JSPRJasper Therapeutics | vensobafusp alfa bispecific · renal | interim_analysis | Watch | large impact 60% confidence | document | "The Company expects to report initial interim data from the IgAN basket study by year-end 2026." Stage 1 IgAN cohort (n=18) enrollment complete; window is document date through 2026-12-31. |
| 2026-12-01 → 2026-12-31 | 56d | KODKodiak Sciences | KSI-101 bispecific · ophthalmology | topline_results | Core | small impact 45% confidence | document | "we remain on track to announce topline data in December 2026 for KSI-101 in the Phase 3 PEAK study in patients with macular edema secondary to inflammation (MESI)" (Pivotal Analysis 1). |
| 2026-07-01 → 2026-12-31 open | 56d | KPTIKaryopharm Therapeutics | selinexor small molecule · hematology | topline_results | Watch | large impact 60% confidence | document | "Topline data from the Phase 2 SENTRY-2 60 mg cohort expected in the second half of 2026." Selinexor monotherapy in JAKi-naive myelofibrosis with moderate thrombocytopenia; 60 mg cohort fully enrolled. Window per "second half of 2026". |
| 2026-07-01 → 2026-12-31 open | 56d | KPTIKaryopharm Therapeutics | selinexor + pomalidomide + dexamethasone small molecule · hematology | topline_results | Watch | large impact 60% confidence | document | "Announce topline data from the event-driven Phase 3 XPORT-MM-031 (EMN29) trial expected in the second half of 2026." All-oral selinexor 40 mg + pomalidomide + dexamethasone vs elotuzumab + pomalidomide + dexamethasone in previously treated myeloma; trial sponsored by the European Myeloma Network, KPTI guides the readout. Window per "second half of 2026". |
| 2026-08-03 → 2026-12-31 open | 56d | KRYSKrystal Biotech | KB111 gene therapy · dermatology | interim_analysis | Watch | small impact 88% confidence | document | Q3 2026 release (Nov 2, 2026) reaffirms: "The Company expects to report interim study results before the end of the year" (HALITE-1, KB111 in HHD; enrollment complete at 5 patients, dosing ongoing; window runs from the Aug 3, 2026 guidance date). 10-Q: "We expect to report HALITE-1 interim study results before the end of the year." |
| 2026-08-03 → 2026-12-31 open | 56d | KRYSKrystal Biotech | KB707 gene therapy · oncology | interim_analysis | Watch | small impact 80% confidence | document | "expects to provide an interim clinical update on these patients as well as outline potential development plans for intratumoral KB707 for the treatment of Gorlin syndrome later this year" (3 patients enrolled in OPAL-1, NCT05970497). "Later this year" from Aug 3, 2026 release. | Caveat: the Q3 2026 release (Nov 2, 2026) did not reaffirm this intratumoral KB707 update; no newer timing given. |
| 2026-10-01 → 2026-12-31 open | 56d | KYNBKyntra Bio | FG-3246 adc · oncology | interim_analysis | Watch | large impact 55% confidence | document | "Interim analysis is on track for the fourth quarter of 2026" (Phase 2 monotherapy trial in mCRPC); reconfirmed "on track for the fourth quarter of this year" in Aug 31, 2026 release. 4Q 2026 = 2026-10-01..2026-12-31. |
| 2026-12-01 → 2026-12-31 | 56d | LGNDLigand Pharmaceuticals | ersodetug monoclonal antibody · metabolic | topline_results | Core | small impact 90% confidence | document | Q3 2026 release: "On October 14, 2026, Rezolute announced completion of enrollment in the Phase 3 study of ersodetug in tumor HI and topline data is expected mid-December 2026." "mid-December 2026" widened to the full month. |
| 2026-10-01 → 2026-12-31 open | 56d | LXEOLexeo Therapeutics | LX2020 gene therapy · cardiovascular | interim_analysis | Watch | large impact 42% confidence | document | "12-month data update for all high dose participants in Q4 2026" from ongoing Phase I/II HEROIC-PKP2 trial in PKP2-ACM. Interim update, not topline. |
| 2026-07-01 → 2026-12-31 open | 56d | LYELLyell Immunopharma | ronde-cel cell therapy · hematology | interim_analysis | Watch | small impact 55% confidence | document | 10-Q (Aug 6, 2026): "A progress update from the PiNACLE-H2H trial is expected in the second half of 2026." Phase 3 head-to-head ronde-cel vs axi-cel/liso-cel in 2L LBCL; progress update, not pivotal data (pivotal PiNACLE 3L+ data guided to mid-2027). |
| 2026-10-19 → 2026-12-31 open | 56d | MANEVeradermics | VDPHL01 small molecule · dermatology | topline_results | Watch | small impact 62% confidence | document | 12-month (Part B) data from Phase 2/3 Study '302' in male pattern hair loss. Oct 19, 2026: "Later this year, we also anticipate reporting the longer-term data from Part B of Study '302', further extending the safety findings of VDPHL01 in males through 12 months"; Aug 11, 2026 8-K said 12-month data anticipated in 2H26. |
| 2026-10-01 → 2026-12-31 open | 56d | MBXMBX Biosciences | MBX 4291 peptide · metabolic | topline_results | Watch | large impact 55% confidence | document | Q2 2026 release: "The Company remains on track to report data from the first cohort of the 12-week MAD (Part C) in Q4 2026." Cohort C1 evaluates a 30 mg (once-weekly x 4) + 120 mg and 180 mg (once-monthly) titration regimen in adults with obesity (BMI >= 30). Window = Q4 2026. |
| 2026-11-01 → 2026-12-31 open | 56d | MGNXMacroGenics | MGC028 adc · oncology | topline_results | Watch | small impact 55% confidence | document | "The dose escalation study of MGC028 is ongoing and the Company anticipates providing an update with preliminary clinical results in late 2026." Late 2026 = Nov 1-Dec 31, 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | MIRMMirum Pharmaceuticals | brelovitug monoclonal antibody · infectious | topline_results | Watch | small impact 68% confidence | document | 8-K: "Topline results from the Phase 3 AZURE-4 study ... are expected in the fourth quarter of 2026." |
| 2026-08-05 → 2026-12-31 open | 56d | NAMSNewAmsterdam Pharma | obicetrapib small molecule · metabolic | topline_results | Watch | small impact 80% confidence | document | "Topline data from RUBENS Phase 3 expected around year-end 2026" (Q3 2026 release, Nov 4 2026); RUBENS evaluates obicetrapib alone or with ezetimibe in T2D/metabolic syndrome; enrollment completed Aug 2026 (n=347). |
| 2026-07-01 → 2026-12-31 open | 56d | NMRANeumora Therapeutics | NMRA-898 small molecule · cns | topline_results | Watch | large impact 50% confidence | document | "Neumora is conducting a MAD study with NMRA-898 in healthy volunteers and patients with stable schizophrenia and expects to report data from the study in the second half of 2026." Window per stated "second half of 2026". |
| 2026-10-01 → 2026-12-31 open | 56d | NMRANeumora Therapeutics | NMRA-511 small molecule · cns | topline_results | Watch | small impact 50% confidence | document | "Neumora plans to report data from a MAD expansion cohort evaluating higher doses of NMRA-511 in healthy elderly participants in the fourth quarter of 2026" (Q2 2026 8-K, Aug 14 2026). |
| 2026-12-01 → 2026-12-31 | 56d | ORKAOruka Therapeutics | ORKA-001 monoclonal antibody · dermatology | interim_analysis | Core | small impact 62% confidence | document | "The Company also expects to report 52-week data from EVERLAST-A for all participants in December 2026." 10-Q phrases it as "by the end of 2026". |
| 2026-11-01 → 2026-12-31 open | 56d | OVIDOvid Therapeutics | OV329 small molecule · cns | topline_results | Watch | small impact 55% confidence | document | Q2 2026 release: photo stimulation proof-of-mechanism study of OV329 (5, 7, 9 mg) initiated; "anticipates results near year end 2026" -> late 2026 window. Not otherwise dated. |
| 2026-10-01 → 2026-12-31 open | 56d | PHATPhathom Pharmaceuticals | vonoprazan small molecule · gi hepatology | topline_results | Watch | small impact 72% confidence | document | "Phathom expects to report topline results during the fourth quarter 2026 for the 12-week blinded treatment portion of its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with EoE" (Q3 2026 release; window unchanged). |
| 2026-10-01 → 2026-12-31 open | 56d | PRAXPraxis Precision Medicines | relutrigine small molecule · cns | topline_results | Watch | small impact 62% confidence | document | 10-Q: EMERALD study in broad DEEs "has completed recruitment, with topline results anticipated in the fourth quarter of 2026." |
| 2026-10-01 → 2026-12-31 open | 56d | PYXSPyxis Oncology | micvotabart pelidotin (MICVO) + pembrolizumab adc · oncology | interim_analysis | Watch | large impact 45% confidence | document | "also expects to report updated data from the ongoing Phase 1/2 dose-escalation study evaluating MICVO in combination with pembrolizumab for first-line (1L) R/M HNSCC in the fourth quarter of 2026" |
| 2026-08-13 → 2026-12-31 open | 56d | RANIRani Therapeutics Holdings | RT-114 peptide · metabolic | interim_analysis | Watch | small impact 55% confidence | document | "additional data from the dose expansion cohort expected by the end of 2026"; first participants in Phase 1a expansion cohort (15 healthy volunteers) dosed. Positive initial Phase 1a single-dose data (>150% oral bioavailability vs SC) were first reported July 2026 (recap only in this filing). |
| 2026-10-01 → 2026-12-31 open | 56d | RAPPRapport Therapeutics | RAP-219 small molecule · cns | topline_results | Watch | large downside 60% confidence | document | FOS open-label long-term safety trial: "Initial data from the open-label long-term safety trial in patients from the Phase 2a trial in FOS are expected in the fourth quarter of 2026" (Q3 2026 8-K EX-99.1, Nov 4, 2026; first guided Oct 20, 2026). |
| 2026-10-01 → 2026-12-31 open | 56d | RGNXREGENXBIO | surabgene lomparvovec gene therapy · ophthalmology | topline_results | Watch | large impact 60% confidence | document | "Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE and ASCENT, expected in Q4 2026"; Q4 2026 = 2026-10-01..2026-12-31. With AbbVie (ABBV-RGX-314). Reaffirmed Oct 12, 2026: "topline pivotal data anticipated in the fourth quarter of 2026". | Reaffirmed Oct 21, 2026 (Oct 20 investor event): "the company said it ex[pects]... Q4 pivotal readout" for sura-vec in wet AMD. |
| 2026-08-04 → 2026-12-31 open | 56d | RIGLRigel Pharmaceuticals | R289 small molecule · hematology | interim_analysis | Watch | small impact 72% confidence | document | Q2 2026 release: dose expansion of Phase 1b in R/R lower-risk MDS "on track to be completed in the second half of 2026 ... and share preliminary data by year end." Window = document date to 2026-12-31 (by year end). Preliminary, not topline. ASH 2026 oral session (PR 2026-11-04) is the announced venue for these Phase 1b data; no data disclosed yet. |
| 2026-10-01 → 2026-12-31 open | 56d | RNTXRein Therapeutics | LTI-03 peptide · respiratory | interim_analysis | Watch | large impact 55% confidence | document | 10-Q: "We expect to report initial interim data on some proportion of patients in the fourth quarter of 2026" for the RENEW Phase 2 trial (NCT06968845) in IPF. Sept 4, 2026 science deck refers more broadly to Phase 2 data "in the second half of 2026"; Q4 window is the stated guidance. |
| 2026-12-01 → 2026-12-31 | 56d | RZLTRezolute | ersodetug monoclonal antibody · oncology | topline_results | Core | small impact 45% confidence | document | "the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026". Enrollment complete per 10/14/26 8-K; earlier guidance (9/24/26 8-K/10-K) said before end of 2026. |
| 2026-01-01 → 2026-12-31 open | 56d | SGMTSagimet Biosciences Inc. Series A | TVB-3567 small molecule · dermatology | topline_results | Watch | small impact 85% confidence | document | "Phase 1 clinical trial results anticipated in 2026, Phase 2 proof of concept clinical trial anticipated to begin before the end of 2026, subject to regulatory feedback". Oct 2026 deck notes SAD/MAD/food-effect dosing complete and Phase 2 doses identified; Part D ongoing. |
| 2026-10-01 → 2026-12-31 open | 56d | SLSSELLAS Life Sciences Group | SLS009 small molecule · hematology | topline_results | Watch | small impact 55% confidence | document | Phase 2 trial in newly diagnosed first-line AML: "Topline data expected in Q4 2026." 28 patients enrolled as of Aug 10, 2026; enrollment/dosing ongoing. Window = Q4 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | SLSSELLAS Life Sciences Group | galinpepimut-S peptide · hematology | topline_results | Watch | large impact 85% confidence | document | Phase 3 REGAL trial in AML: Oct 28, 2026 GlobeNewswire release "announced that the pivotal Phase 3 REGAL trial ... reached its pre-specified 80th event, triggering the final analysis"; "Company to Report Topline Primary Endpoint Results this Quarter." Window = Q4 2026 (topline primary endpoint, overall survival). 80th-event trigger recorded separately as event 1138. |
| 2026-10-01 → 2026-12-31 open | 56d | SLXNSilexion Therapeutics Corp | SIL204 sirna · oncology | interim_analysis | Watch | large impact 55% confidence | document | Company guidance in Aug 2026 investor deck: "Early human data regarding SIL-204 expected Q4, 2026"; also lists secondary-endpoint "ctDNA biomarker data (expected early Q4, 2026)". Safety run-in of Phase 2/3 LAPC trial; Q4 2026 window as stated. Sept 30, 2026 release (first patient dosed) reaffirmed "preliminary clinical readouts in the near term"; no change to Q4 2026 window. |
| 2026-07-01 → 2026-12-31 open | 56d | SRPTSarepta Therapeutics | SRP-1003 sirna · rare genetic | topline_results | Watch | large impact 50% confidence | document | "Readouts from our MAD cohorts of our ongoing phase 1/2 studies in DM1 and FSHD remain on track for 2H 2026." 10-Q: SRP-1003 (DM1) "expect to share further data in the second half of 2026." Date is the half-year window; no specific date stated. |
| 2026-07-01 → 2026-12-31 open | 56d | SRPTSarepta Therapeutics | SRP-1001 sirna · rare genetic | topline_results | Watch | large impact 50% confidence | document | "Readouts from our MAD cohorts of our ongoing phase 1/2 studies in DM1 and FSHD remain on track for 2H 2026." 10-Q: SRP-1001 (FSHD) "expect to share further data in the second half of 2026." Window is the stated half-year; no specific date. |
| 2026-11-01 → 2026-12-31 open | 56d | SRRKScholar Rock Holding | SRK-439 monoclonal antibody · rare genetic | topline_results | Watch | small impact 82% confidence | document | "A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well with topline data anticipated in late 2026." Late 2026 = 2026-11-01..2026-12-31. |
| 2026-10-01 → 2026-12-31 open | 56d | TARAProtara Therapeutics | IV Choline Chloride small molecule · metabolic | interim_analysis | Watch | small impact 68% confidence | document | "Company remains on track to report interim results from Phase 2b cohort in 4Q 2026" (Oct 15, 2026 release completing enrollment of the 2b open-label dose-confirmation phase of THRIVE-3); 10-Q: "We anticipate reporting interim results from the dose-confirmation portion of the trial in the fourth quarter of 2026." |
| 2026-10-01 → 2026-12-31 open | 56d | TARAProtara Therapeutics | TARA-002 cell therapy · rare genetic | interim_analysis | Watch | small impact 60% confidence | document | "Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026". Enrollment completion itself is not a catalyst; the guided STARBORN-1 data update is. |
| 2026-07-01 → 2026-12-31 open | 56d | TNGXTango Therapeutics | vopimetostat small molecule · oncology | topline_results | Watch | small impact 55% confidence | document | "Disclose vopimetostat lung cancer monotherapy data in 2H 2026"; 10-Q: "we anticipate providing a safety and efficacy update in 2026" (lung cancer cohort of vopimetostat monotherapy trial). Window = second half of 2026. |
| 2026-07-01 → 2026-12-31 open | 56d | TNGXTango Therapeutics | TNG456 small molecule · oncology | topline_results | Watch | small impact 68% confidence | document | "Release initial TNG456 data in glioblastoma and other cancers in 2H 2026"; 10-Q: "We anticipate providing initial clinical data from this trial in the second half of 2026." Window = second half of 2026. |
| 2026-10-01 → 2026-12-31 open | 56d | TNYATenaya Therapeutics | TN-201 gene therapy · cardiovascular | interim_analysis | Watch | large impact 50% confidence | document | 10-Q: "We expect to present one-year Cohort 2 data and two-year Cohort 1 data from MyPEAK-1 in the fourth quarter of 2026." 8-K of same date says "additional interim data from the MyPEAK-1 clinical trial in the fourth quarter of 2026." Exact date not stated. |
| 2026-10-01 → 2026-12-31 open | 56d | TNYATenaya Therapeutics | TN-401 gene therapy · cardiovascular | interim_analysis | Watch | small impact 50% confidence | document | 10-Q: "We expect to present interim Cohort 2 results in the fourth quarter of the year." 8-K: "Tenaya expects to report additional interim data from the RIDGE-1 clinical trial in the fourth quarter of 2026." Exact date not stated. |
| 2026-08-05 → 2026-12-31 open | 56d | TRDAEntrada Therapeutics | ENTR-601-44 aso · rare genetic | topline_results | Watch | large impact 40% confidence | document | "Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026" (Oct 14, 2026 GlobeNewswire release, reaffirming Aug 5, 2026 guidance). Window per "by the end of 2026" rule from original guidance date. |
| 2026-10-01 → 2026-12-31 open | 56d | TRVITrevi Therapeutics | Haduvio (nalbuphine ER) / LAKE small molecule · respiratory | interim_analysis | Watch | small impact 75% confidence | document | Phase 2b LAKE (RCC) sample size re-estimation: "once 50% of the participants complete treatment which is expected to occur in the fourth quarter of 2026. The Company will report the outcome of the SSRE once available." |
| 2026-10-01 → 2026-12-31 open | 56d | TVRDTvardi Therapeutics | TTI-101 small molecule · oncology | topline_results | Watch | large impact 60% confidence | document | "4Q 2026: TTI-101 Phase 1b/2 HCC topline data" (8-K business update, Aug 14, 2026). 10-Q: topline data across the three cohorts of the REVERT LIVER CANCER Phase 1b/2 trial in HCC expected in Q4 2026. |
| 2026-07-01 → 2026-12-31 open | 56d | VIRVir Biotechnology | VIR-5818 bispecific · oncology | interim_analysis | Watch | small impact 72% confidence | document | "The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818 ... in the second half of 2026." HER2-targeted PRO-XTEN dual-masked T-cell engager, monotherapy and with pembrolizumab. |
| 2026-10-01 → 2026-12-31 open | 56d | VIRVir Biotechnology | elebsiran and tobevibart other · gi hepatology | topline_results | Watch | small impact 50% confidence | document | "Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026." Combo of siRNA elebsiran + anti-HBsAg mAb tobevibart in chronic hepatitis delta. |
| 2026-10-01 → 2026-12-31 open | 56d | VKTXViking Therapeutics | VK3019 peptide · metabolic | topline_results | Watch | small impact 72% confidence | document | Phase 1 SAD study of DACRA VK3019 in healthy adults: "The company expects to complete the SAD study later this quarter"; 4-week MAD study guided to start 1Q27. |
| 2026-10-01 → 2026-12-31 open | 56d | VRDNViridian Therapeutics | VRDN-008 bispecific · immunology | topline_results | Watch | small impact 80% confidence | document | "Viridian expects to announce VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio in Q4 2026" (Q3 2026 release, 2026-11-04; 10-Q same day: "data on track for the fourth quarter of 2026"). Window narrowed from earlier 2H 2026 guidance. Half-life extended bispecific FcRn inhibitor. |
| 2026-10-01 → 2026-12-31 open | 56d | VYGRVoyager Therapeutics | VY7523 monoclonal antibody · cns | interim_analysis | Watch | large impact 55% confidence | document | "Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer's disease"; 10-Q: initial tau PET imaging efficacy data, enrollment completed Q4 2025. |
| 2026-10-01 → 2026-12-31 open | 56d | WVEWave Life Sciences | WVE-007 sirna · metabolic | topline_results | Watch | large impact 50% confidence | document | Q3 2026 release (2026-10-27): "Wave expects to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026." Narrowed from prior H2 2026 guidance; INLIGHT Phase 1 SAD 600 mg cohort. |
| 2026-10-01 → 2026-12-31 open | 56d | WVEWave Life Sciences | WVE-006 aso · rare genetic | topline_results | Watch | small impact 60% confidence | document | Q3 2026 release (2026-10-27): "Wave expects to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026." RestorAATion-2 600 mg monthly multidose cohort; narrowed from prior H2 2026 guidance. Earlier single-dose data disclosed May 2026. |
| 2026-10-26 → 2026-12-31 open | 56d | XNCRXencor | XmAb942 monoclonal antibody · immunology | interim_analysis | Watch | small impact 68% confidence | document | 2026-10-26 company presentation timeline: XmAb942 (Xtend TL1A, IBD+) in IBD+ ... "Update on progress achieved in Phase 2b XENITH-UC study ~YE26"; approximate year-end 2026 window (document date to 2026-12-31). Separate from the ~2H27 primary endpoint analysis. |
| 2026-10-01 → 2026-12-31 open | 56d | ZBIOZenas BioPharma | obexelimab monoclonal antibody · immunology | topline_results | Watch | large impact 60% confidence | document | "Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026"; 10-Q adds "topline results, including biomarker data, in the fourth quarter of 2026". |
| 2026-10-01 → 2026-12-31 open | 56d | ZURAZura Bio | tibulizumab bispecific · dermatology | topline_results | Watch | large impact 72% confidence | document | TibuSHIELD Phase 2 in hidradenitis suppurativa enrollment complete (247 participants). Q3 2026 8-K (2026-10-27): "Topline data remains on track for the fourth quarter of 2026"; 8-K dated 2026-07-01/2026-08-17 said "fourth quarter of 2026." |
| 2026-11-01 → 2027-01-31 open | 87d | OCSOculis Holding | Licaminlimab monoclonal antibody · ophthalmology | topline_results | Watch | large impact 50% confidence | document | Q3 2026 release on PREDICT-1 registrational symptoms trial in TNFR1-mediated dry eye disease: "Patient randomization is now complete ... Topline results are anticipated around year-end 2026." No month/day given; window covers late 2026 through January 2027. Same guidance in the Oct 7, 2026 release ("around year-end"). |
| 2026-08-06 → 2027-01-31 open | 87d | PEPGPepGen | PGN-EDODM1 aso · cns | interim_analysis | Watch | large impact 60% confidence | document | "Update from the OLE study is expected by early January." OLE enrollment totals 16 participants after DSMB approved escalation from 5 mg/kg to 10 mg/kg; exact date not stated. |
| 2027-01-01 → 2027-01-31 | 87d | SXTP60 DEGREES PHARMACEUTICALS, INC | tafenoquine small molecule · infectious | topline_results | Core | large impact 55% confidence | document | "30 Hospital subjects randomized... Blinded follow-up completes in early January 2027; unblinding follows." Study remains blinded; no efficacy data yet. Earlier release: plans to report hospitalized babesiosis study results in January 2027. |
| 2026-11-01 → 2027-02-28 open | 115d | MAZEMaze Therapeutics | MZE829 small molecule · renal | topline_results | Watch | — | document | "expects to announce updated data in late 2026 or early 2027 on three 10-15 patient cohorts: AMKD without diabetes, AMKD with diabetes and AMKD with severe FSGS" (also cited in Aug 17 release). Updated Phase 2 HORIZON data. |
| 2027-01-01 → 2027-03-31 | 146d | ABSIAbsci | ABS-201 monoclonal antibody · dermatology | topline_results | Watch | — | document | "full 26-week readout in early 2027"; 10-Q: "full proof-of-concept data in early 2027" from HEADLINE Phase 1/2a in pattern hair loss. |
| 2027-01-01 → 2027-03-31 | 146d | ACIUAC Immune | ACI-19764 small molecule · cns | interim_analysis | Watch | small impact 62% confidence | document | "initial results expected early in 2027" (Phase 1b anti-inflammatory/hsCRP cohort); earlier guidance was "by year end" on 2026-08-20, now pushed to early 2027. Table also lists H1 2027. |
| 2027-01-01 → 2027-03-31 | 146d | AKTSAktis Oncology | AKY-1189 radiopharma · oncology | interim_analysis | Watch | — | document | "Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 clinical trial in the first quarter of 2027." Phase 1b in locally advanced/metastatic urothelial and other Nectin-4 expressing tumors. |
| 2027-01-01 → 2027-03-31 | 146d | ANVSAnnovis Bio | buntanetap small molecule · cns | topline_results | Watch | — | document | Q2 2026 release (Aug 14, 2026): "The Company plans a database lock for the 6-month analysis in Q1 2027, with the top-line symptomatic data readout anticipated in the same quarter." Phase 3 AD study (850 patients, pTau217+), 6-month symptomatic readout; ADAS-Cog13 and ADCS-iADL co-primary endpoints. Originally guided in the 2026-07-09 release: "Q1 2027: 6-month symptomatic top-line data readout." |
| 2027-01-01 → 2027-03-31 | 146d | ARQTArcutis Biotherapeutics | ZORYVE (roflumilast) foam 0.3% small molecule · dermatology | topline_results | Watch | — | document | Phase 2 proof-of-concept hidradenitis suppurativa study still enrolling; results and program advancement decisions expected "first quarter of 2027". |
| 2027-01-01 → 2027-03-31 | 146d | AVIRAtea Pharmaceuticals | bemnifosbuvir/ruzasvir (BEM/RZR) small molecule · gi hepatology | topline_results | Watch | — | document | "Topline results are expected in early Q1 2027" for C-FORWARD Phase 3 (ex-North America, >880 patients enrolled June 2026); 10-Q: "expects to report topline results from C-FORWARD early in the first quarter 2027". |
| 2027-01-01 → 2027-03-31 | 146d | AXSMAxsome Therapeutics | solriamfetol small molecule · cns | topline_results | Watch | small impact 80% confidence | document | "The Company anticipates topline results in the first quarter of 2027" (solriamfetol in binge eating disorder, ENGAGE Phase 3); target enrollment reached. Window narrowed from 4Q 2026 (prior guidance) per 3Q 2026 business update. |
| 2027-01-01 → 2027-03-31 | 146d | BMEABiomea Fusion | icovamenib small molecule · metabolic | topline_results | Watch | — | document | "The Company anticipates reporting topline results for the Week 26 primary endpoint in the first quarter of 2027" (COVALENT-211, insulin-deficient T2D; enrollment complete, n=64). Also repeated in Q2 release "26-week primary endpoint data expected in the first quarter of 2027". |
| 2027-01-01 → 2027-03-31 | 146d | CBIOCrescent Biopharma | CR-001 bispecific · oncology | topline_results | Watch | — | document | "on track to report initial monotherapy data from ASCEND in the first quarter of 2027" - ORR from 1L NSCLC cohort (up to 12 pts) plus safety/PK/PD in >125 patients. Phase 1/2 ASCEND monotherapy. |
| 2027-01-01 → 2027-03-31 | 146d | CBIOCrescent Biopharma | CR-003 adc · oncology | topline_results | Watch | — | document | "A Phase 1/2 trial of CR-003 (SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the first quarter of 2027." |
| 2026-08-03 → 2027-03-31 open | 146d | CGENCompugen | COM701 monoclonal antibody · oncology | interim_analysis | Watch | — | document | Q2 2026 release: "Compugen anticipates the interim analysis with median progression-free survival data by the first quarter of 2027" (MAIA-ovarian, randomized placebo-controlled, platinum-sensitive ovarian cancer). Window spans from release date to end of Q1 2027. |
| 2026-11-01 → 2027-03-31 open | 146d | COAGHemab Therapeutics Holdings | HMB-002 monoclonal antibody · hematology | interim_analysis | Watch | — | document | 8-K/10-Q: "The Company expects to report additional data from the trial in late 2026 or early 2027." Refers to the ongoing VELORA Pioneer Phase 1/2 trial of HMB-002 in VWD; multiple-dose assessment underway. |
| 2026-11-01 → 2027-03-31 open | 146d | COCPCocrystal Pharma | CDI-988 small molecule · infectious | topline_results | Watch | — | document | "Preliminary efficacy results expected in late 2026 or early 2027"; CEO: "look forward to reporting preliminary results near the end of 2026 or early 2027" for Phase 1b norovirus challenge study (NCT07198139), last subject dosed 2026-09-09. Earlier (2026-08-03 8-K) guided topline data by end of Q4 2026. |
| 2027-01-01 → 2027-03-31 | 146d | CRBPCorbus Pharmaceuticals Holdings | CRB-701 adc · oncology | topline_results | Watch | — | document | "CRB-701 + pembrolizumab data in 1L OPSCC in Q1 2027 / Topline ORR data expected in Q1 2027" (Oct 15, 2026 corporate presentation). |
| 2027-01-01 → 2027-03-31 | 146d | CRVSCorvus Pharmaceuticals | soquelitinib small molecule · oncology | interim_analysis | Watch | — | document | 10-Q: Phase 3 relapsed/refractory PTCL "interim futility analysis is planned after a defined number of progression events occurs. It is anticipated that this will occur sometime in early 2027." Window = Q1 2027 for "early 2027". |
| 2027-01-01 → 2027-03-31 | 146d | CYTKCytokinetics | aficamten small molecule · cardiovascular | topline_results | Watch | — | document | Q3 2026 release: "Recently completed conduct of the adolescent cohort of CEDAR-HCM ... We expect to present topline data in early 2027." 10-Q: "We recently completed cohort 1 of CEDAR-HCM in the third quarter of 2026." |
| 2027-01-01 → 2027-03-31 | 146d | DMACDiaMedica Therapeutics | DM199 protein · cns | interim_analysis | Watch | — | document | "As we approach enrollment of the 200th participant, we estimate that the interim analysis will be completed in the first quarter of 2027." ReMEDy2 Phase 2/3 in acute ischemic stroke; DSMB interim analysis after first 200 participants complete the trial; may stop for futility or set final sample size (300-728). |
| 2027-01-01 → 2027-03-31 | 146d | DSGNDesign Therapeutics | DT-216P2 small molecule · rare genetic | topline_results | Watch | — | document | "data following 12 weeks of treatment expected in the first quarter of 2027" (RESTORE-FA, Friedreich ataxia); reconfirmed 2026-11-04: "12-Week RESTORE-FA Data in Q1 2027". |
| 2027-01-01 → 2027-03-31 | 146d | DYNDyne Therapeutics | z-basivarsen (DYNE-101) aso · rare genetic | topline_results | Watch | — | document | "Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT at 6 months". Q1 2027 window. |
| 2027-01-01 → 2027-03-31 | 146d | EDITEditas Medicine | EDIT-401 gene therapy · metabolic | interim_analysis | Watch | — | document | Initial safety/tolerability data update from the Phase 1/2 Strive trial: "The Company expects to report initial safety and tolerability data in the first quarter of 2027." 10-Q (2026-08-05) similarly guided "a data update in the first quarter of 2027". |
| 2027-01-01 → 2027-03-31 | 146d | HRMYHarmony Biosciences Holdings | BP-205 small molecule · cns | topline_results | Watch | — | document | Nov 4, 2026: "Phase 1b study in sleep-deprived healthy volunteers initiated in Q3 in the US; data expected in Q1 2027" (earlier: "data expected in early 2027"). Q1 2027 = Jan-Mar 2027. |
| 2027-01-01 → 2027-03-31 | 146d | HROWHarrow | TRIESENCE small molecule · ophthalmology | topline_results | Watch | — | document | "The Company's Phase 3 trial evaluating TRIESENCE for the treatment of ocular inflammation and pain following cataract surgery is on track to fully enroll in 2026, with topline data expected in early 2027." Early 2027 = 2027-01-01..2027-03-31. |
| 2027-01-01 → 2027-03-31 | 146d | IBIOiBio | IBIO-600 monoclonal antibody · metabolic | interim_analysis | Watch | — | document | "IBIO-600 Interim Phase 1 data anticipated in 1Q 2027" (Sept 2026 corporate presentation, slide "Anticipated Near Term Catalysts"); Phase 1 SAD study of anti-myostatin antibody. 1Q 2027 = 2027-01-01..2027-03-31. |
| 2027-01-01 → 2027-03-31 | 146d | INBXInhibrx Biosciences | ozekibart (INBRX-109) monoclonal antibody · oncology | topline_results | Watch | — | document | "The Company expects to announce interim results from these cohorts during the first quarter of 2027." Two new Phase 1 CRC cohorts (FOLFIRI+Avastin 2L; Lonsurf+Avastin 3L/4L). |
| 2026-07-01 → 2027-03-31 open | 146d | INKTMiNK Therapeutics | agenT-797 cell therapy · respiratory | interim_analysis | Watch | — | document | 10-Q: "U.S. sites enrolling in parallel and preliminary data expected in the second half of 2026" for randomized Phase 2 C-1300-02 in acute lung injury/AHRF; same-day 8-K says "Additional data are expected in early 2027" - window spans both statements. Preliminary, not company-confirmed topline. |
| 2027-01-01 → 2027-03-31 | 146d | IRLAIRulya Therapeutics | LAM-001 small molecule · respiratory | topline_results | Watch | — | document | "LAM-001 is currently being evaluated in an ongoing Phase 2 trial in BOS, with data anticipated in the first quarter of 2027." Trial fully enrolled Jan 2026; reiterated in Oct 19 2026 corporate presentation (1Q27 BOS Phase 2 data). |
| 2027-01-01 → 2027-03-31 | 146d | LGNDLigand Pharmaceuticals | volixibat small molecule · gi hepatology | topline_results | Watch | — | document | Q3 2026 release: "enrollment was completed in the VANTAGE Phase 2b study of volixibat in cholestatic pruritus due to primary biliary cholangitis (PBC) with topline results expected in the first quarter of 2027" (Mirum-reported). |
| 2027-01-01 → 2027-03-31 | 146d | LXRXLexicon Pharmaceuticals | sotagliflozin small molecule · cardiovascular | topline_results | Watch | — | document | "Topline results are anticipated in the first quarter of 2027." Phase 3 SONATA-HCM in nHCM and oHCM; primary endpoint change from baseline in KCCQ-CSS at Week 26 |
| 2026-08-13 → 2027-03-31 open | 146d | MDWDMediWound | EscharEx protein · other | interim_analysis | Watch | — | document | Q2 2026 release: "The pre-specified interim sample size reassessment and completion of enrollment are expected by the end of the first quarter of 2027" in the Phase III VALUE trial in venous leg ulcers (216 patients). Window runs from the release date to 2027-03-31. Enrollment completion itself is not a separate catalyst. Sep 14, 2026 DSMB pre-specified review found no safety concerns and recommended continuation without modification; timeline unchanged. |
| 2027-01-01 → 2027-03-31 | 146d | MIRMMirum Pharmaceuticals | volixibat small molecule · gi hepatology | topline_results | Watch | — | document | 10-Q: "recently completed enrollment and expect topline data in the first quarter of 2027" (volixibat, cholestatic pruritus in PBC). |
| 2026-11-01 → 2027-03-31 open | 146d | MLTXMoonLake Immunotherapeutics | sonelokimab bispecific · immunology | topline_results | Watch | — | document | Nov 4, 2026 release: "MoonLake expects results of the P-OLARIS trial to become available in early 2027" (narrowed from Aug 10, 2026 guidance of "end of 2026 or early 2027"; window retained to span the original guidance). Phase 2 imaging study in PsA/axSpA. |
| 2027-01-01 → 2027-03-31 | 146d | MLTXMoonLake Immunotherapeutics | sonelokimab bispecific · immunology | topline_results | Watch | — | document | Nov 4, 2026 release: "Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027"; milestones list: "Expected to announce Week 16 topline results in Q1 2027". IZAR-2 Week 16 readout in TNF-IR PsA (with risankizumab active reference). |
| 2027-01-01 → 2027-03-31 | 146d | MSLESatellos Bioscience | forazapadin small molecule · rare genetic | topline_results | Watch | — | document | Sep 30, 2026 release: "we now intend to share topline clinical data in the first quarter of 2027" for BASECAMP Phase 2 in DMD; company says it is "adjusting our previous plan for releasing data" (prior guidance was Q4 2026). |
| 2027-01-01 → 2027-03-31 | 146d | NAMSNewAmsterdam Pharma | obicetrapib small molecule · cardiovascular | interim_analysis | Watch | — | document | "PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027"; DSMB-run interim (blinded to company), recommendation may stop trial for efficacy/futility or continue to end 2027. 10-Q adds "We expect to receive the DSMB's recommendation ... in the first quarter of 2027." |
| 2027-01-01 → 2027-03-31 | 146d | NSRXNasus Pharma | NS002 small molecule · immunology | topline_results | Watch | — | document | Guidance first given 7/28/2026: "advancing NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027"; reaffirmed in the 9/14/2026 6-K ("anticipates topline data readout from the study in the first quarter of 2027"). Pivotal study planned to start Q4 2026. |
| 2027-01-01 → 2027-03-31 | 146d | OCGNOcugen | OCU400 gene therapy · ophthalmology | topline_results | Watch | — | document | "Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical trial with a topline data readout expected in the first quarter of 2027." Phase 3 in retinitis pigmentosa; enrollment complete (N=140). |
| 2027-01-01 → 2027-03-31 | 146d | OLMAOlema Pharmaceuticals | palazestrant small molecule · oncology | topline_results | Watch | — | document | Q2 2026 release: "we now expect to report top-line data in the first quarter of 2027" from pivotal Phase 3 OPERA-01 (monotherapy, 2L/3L ER+/HER2- MBC); enrollment complete. |
| 2027-01-01 → 2027-03-31 | 146d | ORKAOruka Therapeutics | ORKA-002 monoclonal antibody · dermatology | topline_results | Watch | — | document | "The Company now expects to report Week 16 data from ORCA-SURGE, a Phase 2 trial in moderate-to-severe PsO, in the first quarter of 2027." Timing accelerated from prior guidance. |
| 2026-10-01 → 2027-03-31 open | 146d | PDSBPDS Biotechnology | PDS0301 protein · oncology | interim_analysis | Watch | — | document | "Q4-2026/Q1-2027 Biochemically recurrent prostate cancer (Interim readout)" — NCI-partnered PDS0301 + enzalutamide study; first of five guided PDS0301 readouts. |
| 2027-01-01 → 2027-03-31 | 146d | PHVSPharvaris | deucrictibant XR small molecule · immunology | topline_results | Watch | — | document | "Topline data from Part 1 of CREAATE (NCT07266805) ... are anticipated in the first quarter of 2027." CREAATE: prophylaxis of AAE-C1INH attacks. |
| 2027-01-01 → 2027-03-31 | 146d | PMNProMIS Neurosciences | PMN310 monoclonal antibody · cns | topline_results | Watch | — | document | "unblinded 12-month topline data, including the full safety dataset, an expanded biomarker panel, and clinical cognitive outcome measures, in the first quarter of 2027" — after database lock, following completion of 12-month dosing in Q4 2026. |
| 2027-01-01 → 2027-03-31 | 146d | REPLReplimune Group | RP2 (sturlimgene erparepvec) gene therapy · oncology | interim_analysis | Watch | — | document | "Phase 2/3 transition is expected in Q1 2027" for the registration-directed REVEAL study of RP2 + nivolumab in metastatic uveal melanoma (company-guided milestone, not a stated topline readout). |
| 2027-01-01 → 2027-03-31 | 146d | RNACCartesian Therapeutics | Descartes-08 cell therapy · cns | topline_results | Watch | — | document | Q2 2026 (2026-08-06): "data expected in 1Q27"; reaffirmed Q3 2026 release (2026-11-05): "Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27". Primary endpoint MG-ADL >=3-pt improvement at Month 4. |
| 2027-01-01 → 2027-03-31 | 146d | SEPNSepterna | SEP-479 small molecule · metabolic | topline_results | Watch | — | document | "Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027" (Q2 2026 8-K release; 10-Q repeats). MAD dosing extended to 14 days to characterize steady-state PK. Hypoparathyroidism PTH1R agonist. |
| 2027-01-01 → 2027-03-31 | 146d | SLDBSolid Biosciences | SGT-212 gene therapy · rare genetic | interim_analysis | Watch | — | document | 10-Q FALCON Phase 1b: "with initial data anticipated in the first quarter of 2027, subject to participant enrollment." |
| 2027-01-01 → 2027-03-31 | 146d | SNDXSyndax Pharmaceuticals | axatilimab + ruxolitinib monoclonal antibody · immunology | topline_results | Watch | small impact 72% confidence | document | "The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027." (3Q26 release, Nov 2, 2026; previously guided to Q4 2026) |
| 2027-01-01 → 2027-03-31 | 146d | SPRYARS Pharmaceuticals | ARS-2 small molecule · dermatology | interim_analysis | Watch | — | document | "ARS Pharma expects interim Phase 2b data in the first quarter of 2027" (Q2 2026 release, 2026-08-13). Caveat: enrollment complete in interim population; each patient must log three CSU flare episodes, so timing depends on patient completion. |
| 2027-01-01 → 2027-03-31 | 146d | SRPTSarepta Therapeutics | ELEVIDYS gene therapy · rare genetic | topline_results | Watch | — | document | "For ELEVIDYS, full enrollment of ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027." Q1 2027 window. Cohort 8 (Study 9001-103) evaluates sirolimus immunosuppression in non-ambulant Duchenne patients. |
| 2027-01-01 → 2027-03-31 | 146d | TECXTectonic Therapeutic | TX45 protein · cardiovascular | topline_results | Watch | — | document | "topline results anticipated in early Q1 2027" for the APEX Phase 2 trial in PH-HFpEF (enrollment complete June 2026; IDMC recommended continuation in July 2026). |
| 2026-11-01 → 2027-03-31 open | 146d | TGTXTG Therapeutics | ublituximab monoclonal antibody · cns | topline_results | Watch | — | document | "Announce topline Phase 3 data for subcutaneous BRIUMVI year-end 2026/first quarter 2027"; 10-Q: "expected around year-end 2026 or first quarter 2027". Phase 3 fully enrolled. |
| 2027-01-01 → 2027-03-31 | 146d | TLSATiziana Life Sciences | foralumab monoclonal antibody · cns | topline_results | Watch | — | document | Phase 2 randomized, placebo-controlled trial in early/mild Alzheimer's disease; last patient began dosing. "Topline data are anticipated to be announced in Q1 2027." |
| 2027-01-01 → 2027-03-31 | 146d | TRAXFirst Tracks Biotherapeutics | ANB033 monoclonal antibody · gi hepatology | topline_results | Watch | — | document | Q3 2026 release (Nov 3, 2026): "Enrollment complete with top-line data anticipated in Q1 2027" - Phase 1b Cohort 2 (mucosal healing) in celiac disease; reaffirms prior Q1 2027 guidance. |
| 2027-01-01 → 2027-03-31 | 146d | TRDAEntrada Therapeutics | ENTR-601-44 aso · rare genetic | topline_results | Watch | — | document | Q2 2026 release: "ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027". |
| 2027-01-01 → 2027-03-31 | 146d | TTRXTurn Therapeutics | GX-03 other · dermatology | topline_results | Watch | — | document | "Phase 2 RCT trial underway for moderate to severe AD, topline results expected Q1 2027"; milestones slide "Q1 2027: Topline Readout". Prior guidance (July 2026 deck) was Q4 2026. |
| 2027-03-01 → 2027-03-31 | 146d | TYRATyra Biosciences | dabogratinib small molecule · rare genetic | topline_results | Core | — | document | "Initial results from the safety sentinel cohort, including 6-month annualized height velocity and safety data for dose levels 1-5 ... expected to be reported at the end of Q1 2027" (BEACH301, achondroplasia, ~25 children). |
| 2027-01-01 → 2027-03-31 | 146d | VERUVeru | enobosarm small molecule · metabolic | interim_analysis | Watch | — | document | "Results of an interim analysis assessing lean body mass and fat mass as measured by DXA after patients have completed 32 weeks is expected in the first quarter of calendar year 2027." Phase 2b PLATEAU fully enrolled (239 patients). |
| 2027-01-01 → 2027-03-31 | 146d | VIRVir Biotechnology | elebsiran and tobevibart other · gi hepatology | topline_results | Watch | — | document | "Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027." ECLIPSE 2 (switch from bulevirtide, Ph3) and ECLIPSE 3 (Ph2b vs bulevirtide) reported in same guidance window. |
| 2027-01-01 → 2027-03-31 | 146d | VYGRVoyager Therapeutics | VY1706 gene therapy · cns | interim_analysis | Watch | — | document | "Early 2027: Potential for initial acute safety data with VY1706, pending enrollment"; 10-Q: "initial acute safety data, which we anticipate announcing in early 2027, pending enrollment progress and timing". Oct-21 8-K still refers to first quarter of 2027. |
| 2027-01-01 → 2027-06-30 | 237d | ACETAdicet Bio | prula-cel cell therapy · immunology | interim_analysis | Watch | — | document | "First Half 2027: Anticipated clinical data update in systemic sclerosis (SSc)" |
| 2027-01-01 → 2027-06-30 | 237d | ACIUAC Immune | ACI-19764 small molecule · cns | topline_results | Watch | — | document | "Full results from the Phase 1/1b trial are expected in H1 2027"; also "additional data expected in H1 2027". H1 2027 = 2027-01-01..2027-06-30. |
| 2027-01-01 → 2027-06-30 | 237d | ANROAlto Neuroscience | ALTO-300 small molecule · cns | topline_results | Watch | — | document | "Topline data remain expected in 1H 2027 for the ALTO-300 Phase 2b MDD trial". 10-Q also: "We expect to report topline data from this trial in the first half of 2027." Window = 1H 2027. |
| 2026-07-01 → 2027-06-30 open | 237d | ATNMActinium Pharmaceuticals Inc. (Delaware) | Actimab-A radiopharma · oncology | interim_analysis | Watch | — | document | Initial data from the planned Phase 1b basket trial of Actimab-A + pembrolizumab/nivolumab in HNSCC, NSCLC, GBM and MSI-high CRC. 10-Q: "We expect to report initial data from this trial in 2H:2026 or 1H:2027." Trial described as intended to be conducted. |
| 2027-01-01 → 2027-06-30 | 237d | BLSMBlossomHill Therapeutics | BH-30643 small molecule · oncology | interim_analysis | Watch | — | document | "We plan to report updated Phase 1 data on durability of response in the C797S population in the first half of 2027" (10-Q); 8-K: "1H 2027: Updated Phase 1 data, including C797S durability". |
| 2027-01-01 → 2027-06-30 | 237d | BLSMBlossomHill Therapeutics | BH-30236 small molecule · hematology | interim_analysis | Watch | — | document | "We expect to report updated data on safety and anti-leukemic effects from the BH-30236 Phase 1 trial in the first half of 2027" (R/R AML and HR-MDS). |
| 2027-04-01 → 2027-06-30 | 237d | BMEABiomea Fusion | icovamenib small molecule · metabolic | topline_results | Watch | — | document | "COVALENT-212 Phase II enrollment ... is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027". Enrollment expected complete before year end 2026. |
| 2027-01-01 → 2027-06-30 | 237d | CLYMClimb Bio | CLYM116/MIL116 monoclonal antibody · renal | topline_results | Watch | — | document | "NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in the first half of 2027" (IgAN). Global Phase 3 initiation in 2027 pending regulatory feedback (not a catalyst row). |
| 2027-04-01 → 2027-06-30 | 237d | COYACoya Therapeutics | COYA 302 protein · cns | topline_results | Watch | — | document | "Topline data from the double-blind treatment phase are anticipated in early Q2 2027" (Oct 5, 2026 8-K, ALSTARS Ph2/3 ALS, full enrollment of 120 announced); reaffirmed context Oct 14, 2026 8-K. Window widened to all of Q2 2027 per "early Q2". Earlier guidance was Q1 2027 (Aug 11, 2026 release). Double-blind phase data; extension continues. |
| 2027-01-01 → 2027-06-30 | 237d | CTMXCytomX Therapeutics | varsetatug masetecan adc · oncology | interim_analysis | Watch | — | document | "A Phase 1 combination study of Varseta-M and bevacizumab is ongoing... Initial clinical data is anticipated in 1H 2027" (late-line CRC). 1H 2027 = 2027-01-01..2027-06-30. |
| 2027-01-01 → 2027-06-30 | 237d | CTMXCytomX Therapeutics | CX-801 protein · oncology | interim_analysis | Watch | — | document | "Initial clinical data for CX-801 in combination with KEYTRUDA(R) in advanced melanoma is expected in the first half of 2027." 1H 2027 = 2027-01-01..2027-06-30. |
| 2027-01-01 → 2027-06-30 | 237d | DNLIDenali Therapeutics | DNL593 (PTV:PGRN) protein · cns | topline_results | Watch | — | document | "Data are expected in the first half of 2027." (Q3 2026 release, Nov 3 2026) — narrowed from prior year-only "in 2027" expectation. Phase 1/2 in FTD-GRN; enrollment complete (n=40). Orphan Drug Designation granted Aug 2026. |
| 2027-01-01 → 2027-06-30 | 237d | DNLIDenali Therapeutics | DNL628 (OTV:MAPT) aso · cns | interim_analysis | Watch | — | document | "Initial clinical biomarker data from the ongoing Phase 1b study of DNL628 in participants with Alzheimer's disease are expected in the first half of 2027." Biomarker data only, not full topline. |
| 2027-01-01 → 2027-06-30 | 237d | DNLIDenali Therapeutics | DNL151 (LRRK2 inhibitor) small molecule · cns | topline_results | Watch | — | document | BEACON Phase 2a in LRRK2-variant Parkinson's: "Data from BEACON are expected in the first half of 2027." Idiopathic PD development discontinued after LUMA failure; BEACON continues independently. |
| 2027-01-01 → 2027-06-30 | 237d | EIKNEikon Therapeutics | EIK1005 small molecule · oncology | interim_analysis | Watch | — | document | "Eikon expects additional results from the combination of EIK1005 with pembrolizumab to be available in the first half of 2027" (company release, 2026-10-23). First half 2027 = 2027-01-01..2027-06-30. |
| 2027-04-01 → 2027-06-30 | 237d | EQEquillium | EQ504 small molecule · gi hepatology | topline_results | Watch | — | document | "Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027" (10/26/2026 PR/SEC 8-K Ex-99.1, first subject dosed in EQ504 Phase 1, NCT07869225). Supersedes 8/13/2026 "data expected approximately six months after Q4 2026 initiation". Q2 = Apr-Jun 2027. |
| 2027-01-01 → 2027-06-30 | 237d | ERASErasca | ERAS-0015 small molecule · oncology | interim_analysis | Watch | — | document | Key upcoming milestones: "Phase 1 monotherapy expansion data expected in the first half of 2027" and "Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027" (AURORAS-1) |
| 2027-01-01 → 2027-06-30 | 237d | FATEFate Therapeutics | FT836 cell therapy · oncology | interim_analysis | Watch | — | document | Q2 2026 8-K: "The Company expects to provide the next clinical update on FT836 in the first half of 2027." Guided next clinical update after ASCO 2026 preliminary Phase 1 data (KRASwt mCRC, multi-dosing + SOC chemo cohort); company did not call it topline. |
| 2027-04-01 → 2027-06-30 | 237d | FDMT4D Molecular Therapeutics | 4D-150 gene therapy · ophthalmology | topline_results | Watch | — | document | "4FRONT-1 ... topline data expected in Q2 2027" (Q2 2026 earnings release). Enrollment completed Feb 2026; randomization completed Mar 2026 (N=523). |
| 2027-01-01 → 2027-06-30 | 237d | HURATuHURA Biosciences | IFx-2.0 small molecule · oncology | interim_analysis | Watch | — | document | Q2 2026 release milestones: "1H2027: Expect preliminary results from IR study IFX-2.0 with Keytruda for deep seated MCC." |
| 2027-01-01 → 2027-06-30 | 237d | HURATuHURA Biosciences | TBS-2025 monoclonal antibody · oncology | interim_analysis | Watch | — | document | Q2 2026 release milestones: "1H 2027: Expect preliminary safety and response data for VISTA in mutated NMP1 r/r AML." VISTA-inhibiting mAb TBS-2025. |
| 2027-01-01 → 2027-06-30 | 237d | IKTInhibikase Therapeutics | IKT-001 small molecule · cardiovascular | interim_analysis | Watch | — | document | Corporate overview: "1H 2027 Interim safety readout for Part A of Phase 3 IMPROVE-PAH Study (n=50)"; also "First Half 2027 - Interim Safety Readout". |
| 2027-01-01 → 2027-06-30 | 237d | IMRXImmuneering | atebimetinib (IMM-1-104) small molecule · oncology | topline_results | Watch | — | document | Q3 2026 release (Oct 29, 2026): "Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027"; CEO: "provide an update on topline data from the atebimetinib + mGnP arm ... in the first half of 2027." Window = 1H 2027 (Jan-Jun). Follow-up extended as patients live longer than projected. |
| 2027-01-01 → 2027-06-30 | 237d | IMTXImmatics | anzu-cel (IMA203) cell therapy · oncology | topline_results | Watch | — | document | "The Company expects to disclose topline data from the final PFS analysis in the first half of 2027" - SUPRAME Phase 3 in advanced melanoma; interim/final PFS analyses replaced by a single streamlined final analysis. Half-year window used as stated. |
| 2027-01-01 → 2027-06-30 | 237d | IPHAInnate Pharma | monalizumab monoclonal antibody · oncology | topline_results | Watch | — | document | SEC 6-K exhibit: "AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously." Supersedes 17-Sep-2026 HY-2026 guidance of H2 2026. AZ-sponsored; Innate guiding timing. Same release also indexed by Google News/Business Wire. |
| 2027-04-01 → 2027-06-30 | 237d | IRDOpus Genetics | OPGx-BEST1 gene therapy · rare genetic | topline_results | Watch | — | document | "Cohort 2 over-enrolled, with dosing expected to be completed in Q4 2026 and topline 3-month data expected in Q2 2027." Company also guides 6-month low-dose Cohort 1 (BVMD, n=3) data to the same Q2 2027 window. Q2 2027 = 2027-04-01..2027-06-30. |
| 2027-04-01 → 2027-06-30 | 237d | JSPRJasper Therapeutics | vensobafusp alfa bispecific · renal | interim_analysis | Watch | — | document | 10-Q: "updated data in the second quarter of 2027, and we plan to report interim data from Stage 2 of the study in the second quarter of 2027" (KP-104 Phase 2 renal basket). Both Q2 2027 disclosures fall in this window. |
| 2027-01-01 → 2027-06-30 | 237d | KARDKardigan | danicamtiv small molecule · cardiovascular | topline_results | Watch | — | document | "The Company expects to share Phase 2b topline data in the first half of 2027" for KINSHIP-DCM (Cohort 1 MYH7/TTN); Phase 3 enrollment underway as of 8/11/2026. |
| 2027-01-01 → 2027-06-30 | 237d | KARDKardigan | ataciguat small molecule · cardiovascular | topline_results | Watch | — | document | "expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027" (KATALYST-AV, moderate CAVS). |
| 2027-01-01 → 2027-06-30 | 237d | KARDKardigan | tonlamarsen aso · cardiovascular | topline_results | Watch | — | document | "expects to share Phase 2 topline data in the first half of 2027" (KARDINAL-ASH, acute severe hypertension); first patient randomized in Q2 2026. |
| 2027-01-01 → 2027-06-30 | 237d | KLRSKalaris Therapeutics | TH103 protein · ophthalmology | interim_analysis | Watch | — | document | "Preliminary data from the Phase 1b/2 study is expected in the first half of 2027." Phase 1b/2 multiple-ascending dose study in nAMD; dosing ongoing as of Aug 11, 2026. |
| 2027-04-01 → 2027-06-30 | 237d | KODKodiak Sciences | KSI-101 bispecific · ophthalmology | topline_results | Watch | — | document | "Completion of enrollment in the second pivotal cohort ... is expected in the fourth quarter of 2026, with topline data anticipated in the second quarter of 2027" (Pivotal Analysis 2: PEAK 301-600 and PINNACLE 1-300). |
| 2027-01-01 → 2027-06-30 | 237d | KROSKeros Therapeutics | rinvatercept protein · rare genetic | topline_results | Watch | — | document | "Initial data expected in the first half of 2027" from Phase 2 DMD trial; first patient dosed Sept 28, 2026. Window covers first half of 2027. Guidance also reiterated in Aug 3, 2026 Q2 release. |
| 2027-01-01 → 2027-06-30 | 237d | KRYSKrystal Biotech | KB407 gene therapy · respiratory | interim_analysis | Watch | small impact 60% confidence | document | "The Company expects to enroll and dose three additional patients before year end, with interim study results now anticipated in the first half of 2027" (repeat-dose 24-week CF safety study, NCT05504837). Slipped from prior before-year-end 2026 guidance. |
| 2027-01-01 → 2027-06-30 | 237d | KRYSKrystal Biotech | KB707 gene therapy · oncology | interim_analysis | Watch | — | document | "plans to report updated interim clinical results from KYANITE-1 and potential registrational study plans in 1H 2027" (inhaled KB707 + chemotherapy cohort, NSCLC) |
| 2027-02-01 → 2027-06-30 | 237d | KRYSKrystal Biotech | KB803 gene therapy · ophthalmology | topline_results | Watch | small impact 80% confidence | document | "The Company now expects the last patient visit in February 2027 with top-line results reported shortly thereafter" (IOLITE, registrational). Changed from prior 4Q 2026 guidance; 3 additional patients enrolled, two withdrawals replaced. |
| 2027-01-01 → 2027-06-30 | 237d | LBRXLB Pharmaceuticals | LB-102 small molecule · cns | topline_results | Watch | — | document | "it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027" (accelerated from prior 2H 2027 guidance; enrollment-based projection). Registered schizophrenia; Phase 3 placebo-controlled. |
| 2027-04-01 → 2027-06-30 | 237d | LGNDLigand Pharmaceuticals | AVIM Therapy other · cardiovascular | topline_results | Watch | — | document | Q2 2026 release: Orchestra BioMed "is targeting top line data in the second quarter of 2027" for the BACKBEAT pivotal trial of AVIM Therapy; enrollment completion (330 randomized) reported 2026-10-01 in the Q3 release. Q2 2027 = 2027-04-01..2027-06-30. |
| 2027-01-01 → 2027-06-30 | 237d | MANEVeradermics | VDPHL01 small molecule · dermatology | topline_results | Watch | — | document | Topline data from Phase 2/3 Study '306' in female pattern hair loss (n=556, enrollment complete). Oct 19, 2026: "a readout of topline data anticipated in the first half of 2027"; Aug 11, 2026 8-K: "expects to report topline data in the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | MGNXMacroGenics | lorigerlimab bispecific · oncology | topline_results | Watch | — | document | LINNET in advanced gynecologic cancers: "anticipates reporting updated study results in the first half of 2027." First half of 2027 = Jan 1-Jun 30, 2027. |
| 2027-04-01 → 2027-06-30 | 237d | MGTXMeiraGTx Holdings | AAV2-hAQP1 gene therapy · other | topline_results | Watch | — | document | Phase 2 AQUAx2 (randomized, double-blind, placebo-controlled, 30 sites; enrollment completed Q2 2026) "remains on track for a 12-month pivotal data readout in the second quarter of 2027, which, if positive, would support a BLA filing and potential approval targeted for the end of 2027". Indication: radiation-induced xerostomia. |
| 2027-04-01 → 2027-06-30 | 237d | MLTXMoonLake Immunotherapeutics | sonelokimab bispecific · immunology | topline_results | Watch | — | document | Nov 4, 2026 release: IZAR-1 (PsA) "Expected to announce Week 52 topline results in Q2 2027" (narrowed from H1 2027 guided Aug 10, 2026). Week 16 absolute responses/p values disclosed Aug 2026; placebo comparisons remain blinded until trial completion. |
| 2027-01-01 → 2027-06-30 | 237d | NVCTNuvectis Pharma | NXP900 small molecule · oncology | interim_analysis | Watch | small impact 72% confidence | document | NXP900 Phase 1b combinations (osimertinib in EGFR+ NSCLC; lorlatinib in ALK+ NSCLC): "Update from Phase 1b expected during the first half of 2027." Supersedes Aug 4, 2026 guidance of an update by end-2026. First half 2027 = 2027-01-01..2027-06-30. |
| 2027-01-01 → 2027-06-30 | 237d | OBXObsidian Therapeutics | OBX-115 cell therapy · oncology | interim_analysis | Watch | — | document | "Phase 1 data from the ongoing non-small cell lung cancer (NSCLC) trial expected in the first half of 2027" (8-K 8/3/2026, post-merger closing release). Guided as Phase 1 data, not stated as topline. |
| 2027-04-01 → 2027-06-30 | 237d | OCGNOcugen | OCU410ST gene therapy · ophthalmology | topline_results | Watch | — | document | "Topline results anticipated in the second quarter of 2027, with a BLA submission to follow mid-2027." Pivotal Phase 2/3 GARDian3 in Stargardt disease; enrollment complete. |
| 2027-01-01 → 2027-06-30 | 237d | OPKOPKO Health | — bispecific · oncology | interim_analysis | Watch | — | document | Q3 2026 release reaffirms: "We expect to report initial safety, tolerability, pharmacokinetic and immune data for both studies in the first half of 2027" (ModeX MDX2001 and MDX2004 Phase 1). Sentence names no specific drug, so drug left NULL. |
| 2027-01-01 → 2027-06-30 | 237d | PBMPsyence Biomedical | NPX-5 other · cns | topline_results | Watch | — | document | Investor presentation (Aug 2026): "Estimated top line study results H1 2027" for the NPX-5 25mg psilocybin Phase IIb trial in Adjustment Disorder in cancer/palliative care; also "Projected Upcoming Top line results H1 2027". Range is the stated half-year. |
| 2026-10-05 → 2027-06-30 open | 237d | PCVXVaxcyte | VAX-31 vaccine · infectious | topline_results | Watch | — | document | "Announce topline safety, tolerability and immunogenicity data from the VAX-31 infant Phase 2 ... from both the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | PCVXVaxcyte | VAX-31 vaccine · infectious | topline_results | Watch | — | document | "Company Expects to Report Results from OPUS-2 and OPUS-3 Adult Phase 3 Trials in First Half of 2027." Milestones: "Announce safety, tolerability and immunogenicity data from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of 2027." Single row covers both trials (same VAX-31 drug/window). |
| 2027-01-01 → 2027-06-30 | 237d | PDSBPDS Biotechnology | PDS0301 protein · oncology | topline_results | Watch | — | document | "Q1/Q2-2027 NCI-led - Colorectal cancer with liver metastases (Final data readout)" — final data from NCI-led Phase 2 in MSS/pMMR mCRC with liver metastases. |
| 2027-01-01 → 2027-06-30 | 237d | PEPGPepGen | PGN-EDODM1 aso · cns | topline_results | Watch | — | document | "Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in the first half of 2027." Enrollment in this highest dose cohort to start shortly after DSMB recommended escalation. |
| 2027-04-01 → 2027-06-30 | 237d | PROKProKidney | rilparencel cell therapy · renal | topline_results | Watch | — | document | PROACT 1 (REGEN-006) accelerated-approval efficacy analysis (n~320) eGFR slope topline: "We anticipate topline data readout of the surrogate endpoint (eGFR slope) in the second quarter of 2027." Enrollment for this analysis complete. |
| 2027-01-01 → 2027-06-30 | 237d | PYXSPyxis Oncology | micvotabart pelidotin (MICVO) adc · oncology | interim_analysis | Watch | — | document | "publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in 2L+ R/M HNSCC, which is expected in the first half of 2027" (2026-10-01 8-K). Reconfirmed 2026-11-05 Q3 release: "Updated overall survival data ... expected in the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | QUREuniQure | AMT-260 gene therapy · cns | topline_results | Watch | — | document | "The Company expects to present updated results from the Phase I/IIa study in the first half of 2027" (AMT-260 in refractory mesial temporal lobe epilepsy). Window per "first half of 2027". |
| 2027-01-01 → 2027-06-30 | 237d | RAREUltragenyx Pharmaceutical | avalotcagene ontaparvovec (DTX301) gene therapy · metabolic | topline_results | Watch | — | document | "Data from the second primary endpoint, which evaluates reduction in treatment burden ... are expected in the first half of 2027." Phase 3 Enh3ance in OTC deficiency. |
| 2027-01-01 → 2027-06-30 | 237d | RCUSArcus Biosciences | quemliclustat small molecule · gi hepatology | topline_results | Watch | — | document | "Enrollment was completed in September 2025 for PRISM-1, a Phase 3 trial of quemliclustat combined with gemcitabine/nab-paclitaxel ... Results from this study are expected in the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | RNACCartesian Therapeutics | Descartes-08 cell therapy · immunology | interim_analysis | Watch | — | document | Q3 2026 release (2026-11-05): "Phase 2 TRITON trial of Descartes-08 in myositis ... data from subset of patients expected in 1H27 to inform path forward to pivotal trial." Partial/subset data. |
| 2027-01-01 → 2027-06-30 | 237d | RNACCartesian Therapeutics | — cell therapy · cns | interim_analysis | Watch | — | document | Q2 2026 release: WestGene-partnered in vivo CAR-T Ph1 in MG "expected to initiate in the second half of 2026 with in-human data expected in the first half of 2027"; Q3 2026 release (2026-11-05) says program remains in preclinical development with no new timing. No drug named in the supporting sentence. |
| 2027-01-01 → 2027-06-30 | 237d | RNACCartesian Therapeutics | Descartes-08 cell therapy · immunology | topline_results | Watch | — | document | Q3 2026 release (2026-11-05): "Phase 1/2 HELIOS pediatric trial of Descartes-08 in autoimmune diseases, including JDM ... data expected in 1H27"; enrollment remains ongoing. |
| 2027-01-01 → 2027-06-30 | 237d | RXRXRecursion Pharmaceuticals | REC-617 small molecule · oncology | interim_analysis | Watch | — | document | "REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27" - window = first half of 2027. |
| 2027-01-01 → 2027-06-30 | 237d | RXRXRecursion Pharmaceuticals | REC-3565 small molecule · oncology | interim_analysis | Watch | — | document | "REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27" - window = first half of 2027. |
| 2027-01-01 → 2027-06-30 | 237d | SANASana Biotechnology | SG293 gene therapy · oncology | topline_results | Watch | — | document | "SG293 in non-Hodgkin lymphoma - potential to share first-in-human data in 1H 2027" (Sept 2026 presentation). Earlier 8-K (2026-08-10) guided "as early as this year". |
| 2027-01-01 → 2027-06-30 | 237d | SCTXScribe Therapeutics | STX-1150 gene therapy · cardiovascular | interim_analysis | Watch | — | document | "Scribe anticipates reporting initial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose (SAD) portion of the STX-1150 Phase 1 trial in the first half of 2027." Phase 1 initiated mid-2026 in Australia. |
| 2027-01-01 → 2027-06-30 | 237d | SERSerina Therapeutics | SER-252 small molecule · cns | topline_results | Watch | — | document | "Top-line data from the single-ascending-dose arm targeted for the first half of 2027" (Phase 1b registrational study in advanced Parkinson's disease). Confirmed in 2026-09-09 8-K. |
| 2027-01-01 → 2027-06-30 | 237d | SLDBSolid Biosciences | SGT-501 gene therapy · cardiovascular | interim_analysis | Watch | — | document | 10-Q ARTEMIS Phase 1b: "We anticipate dosing our first participant in the second half of 2026 with initial safety data anticipated in the first half of 2027, subject to participant enrollment." |
| 2027-01-01 → 2027-06-30 | 237d | SPTXSeaport Therapeutics | GlyphAllo small molecule · cns | topline_results | Watch | — | document | "Topline data from the BUOY-1 trial are expected in the first half of 2027." Phase 2b BUOY-1 trial in MDD with or without anxious distress; enrollment on track (reaffirmed in Q3 2026 release, Nov 2, 2026). |
| 2027-01-01 → 2027-06-30 | 237d | STOKStoke Therapeutics | STK-002 aso · ophthalmology | topline_results | Watch | — | document | Phase 1 OSPREY (ADOA), dose escalation: "Dosing in the first two cohorts is complete and dosing in the third cohort is underway with the fourth cohort expected to follow in early 2027. ... Safety and efficacy data are anticipated in the first half of 2027." First half of 2027 = 2027-01-01..2027-06-30. Confirmed in Q3 2026 release (Oct 29, 2026). |
| 2027-01-01 → 2027-06-30 | 237d | STROSutro Biopharma | STRO-004 adc · oncology | interim_analysis | Watch | — | document | "The next STRIVE-01 study update is targeted for the first half of 2027. Initiation of expansion cohorts is planned for the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | TARSTarsus Pharmaceuticals | TP-04 small molecule · ophthalmology | topline_results | Watch | — | document | "The Phase 2 KORE trial evaluating TP-04 ... for the potential treatment of ocular rosacea, continues to progress, with topline data expected in the first half of 2027." First half of 2027 = Jan 1 - Jun 30, 2027. Reaffirmed in Q3 2026 release (2026-11-03): "topline data expected in the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | TARSTarsus Pharmaceuticals | TP-05 small molecule · infectious | topline_results | Watch | — | document | Calliope Phase 2 (Lyme disease prevention) enrollment complete; "Topline data is expected in the first half of 2027, with the potential to support a Phase 3-ready package." H1 2027 = 2027-01-01..2027-06-30. Reaffirmed in Q3 2026 release (2026-11-03): "topline data expected in the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | TRDAEntrada Therapeutics | ENTR-601-45 aso · rare genetic | topline_results | Watch | — | document | 8-K: "on track to report data from Cohort 2 (10 mg/kg) in the first half of 2027, with data from Cohort 3 (up to 15 mg/kg) to follow." Cohort 3 has no stated date. |
| 2027-01-01 → 2027-06-30 | 237d | TSHATaysha Gene Therapies | TSHA-102 gene therapy · cns | topline_results | Watch | — | document | "Topline data from REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 is expected in the first half of 2027." Interim analysis after all 17 patients complete 6 months of follow-up. Dosing complete (n=17). |
| 2027-01-01 → 2027-06-30 | 237d | VNDAVanda Pharmaceuticals | milsaperidone (BYSANTI) small molecule · cns | topline_results | Watch | — | document | "The Phase III study of BYSANTI (milsaperidone) as a once-daily adjunctive treatment for major depressive disorder (MDD), with results expected in the first half of 2027." |
| 2027-01-01 → 2027-06-30 | 237d | VORVor Biopharma | telitacicept protein · immunology | topline_results | Watch | — | document | 10-Q: "Topline data from the trial is anticipated in the first half of 2027" (global Phase 3 in gMG). Window = 2027-01-01..2027-06-30 per the stated first half of 2027; no more precise date given. |
| 2027-01-01 → 2027-06-30 | 237d | WHWKWhitehawk Therapeutics | HWK-007 adc · oncology | interim_analysis | Watch | — | document | 10-Q: "We expect data readouts in the first half of 2027 for each trial" (HWK-007 and HWK-016 Phase 1). 8-K of 2026-08-06 says "initial results expected in 1H 2027". Window widened to full 1H 2027. |
| 2027-01-01 → 2027-06-30 | 237d | WHWKWhitehawk Therapeutics | HWK-016 adc · oncology | interim_analysis | Watch | — | document | 10-Q: "We expect data readouts in the first half of 2027 for each trial" (HWK-007 and HWK-016 Phase 1). Initial Phase 1 results, not stated as topline. |
| 2027-01-01 → 2027-06-30 | 237d | XENEXenon Pharmaceuticals | azetukalner small molecule · cns | topline_results | Watch | — | document | "topline data from X-NOVA2 expected in H1 2027"; Phase 3 MDD study. H1 2027 = 2027-01-01..2027-06-30. |
| 2027-01-01 → 2027-06-30 | 237d | ZNTLZentalis Pharmaceuticals | azenosertib small molecule · oncology | topline_results | Watch | — | document | 10-Q: "We expect to provide a topline readout of DENALI Part 2 in the first half of 2027 to allow for data maturation post full enrollment." Integrated Part 2a/2b/2c dataset designed to support accelerated approval in Cyclin E1-positive PROC; Part 2c still enrolling. |
| 2027-01-01 → 2027-06-30 | 237d | ZURAZura Bio | tibulizumab bispecific · immunology | topline_results | Watch | — | document | TibuSURE Phase 2 in early diffuse cutaneous systemic sclerosis enrollment complete (91 participants). Q3 2026 8-K (2026-10-27): "Topline data remains on track for the first half of 2027"; same guidance in 8-K dated 2026-07-01/2026-08-17. |
| 2027-06-01 → 2027-07-31 | 268d | ACETAdicet Bio | prula-cel cell therapy · immunology | interim_analysis | Watch | — | document | "Mid 2027: Anticipated clinical data update in LN/SLE" |
| 2027-06-01 → 2027-07-31 | 268d | ALLOAllogene Therapeutics | cema-cel cell therapy · oncology | interim_analysis | Watch | — | document | "We anticipate ... conducting an interim EFS analysis in mid-2027" for ALPHA3 (1L consolidation LBCL); window = mid 2027. |
| 2027-06-01 → 2027-07-31 | 268d | ALXOALX Oncology Holdings | evorpacept protein · oncology | topline_results | Watch | — | document | "topline data from 80 patients expected in mid-2027" (ASPEN-09-Breast Phase 2, evorpacept + trastuzumab and chemo in HER2+ mBC); "mid-2027"=2027-06-01..2027-07-31 |
| 2027-06-01 → 2027-07-31 | 268d | ANROAlto Neuroscience | ALTO-100 small molecule · cns | topline_results | Watch | — | document | "Topline data remain expected ... mid-2027 for the ALTO-100 Phase 2b BPD trial". Mid-2027 = 2027-06-01..2027-07-31. |
| 2027-06-01 → 2027-07-31 | 268d | BBOTBridgeBio Oncology Therapeutics | BBO-8520 small molecule · oncology | topline_results | Watch | — | document | "Expanded BBO-8520 plus pembrolizumab dataset in 2L+ KRAS G12C inhibitor-experienced NSCLC expected in mid-2027." Refines earlier Aug 11, 2026 10-Q guidance of updated data in 2H 2026. |
| 2027-06-01 → 2027-07-31 | 268d | BBOTBridgeBio Oncology Therapeutics | BBO-11818 small molecule · oncology | topline_results | Watch | — | document | "Data from BBO-11818 and BBO-10203 internal and standard-of-care combination cohorts in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) expected in mid-2027." |
| 2027-06-01 → 2027-07-31 | 268d | BBOTBridgeBio Oncology Therapeutics | BBO-10203 small molecule · oncology | topline_results | Watch | — | document | "Data from BBO-11818 and BBO-10203 internal and standard-of-care combination cohorts in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) expected in mid-2027." |
| 2027-06-01 → 2027-07-31 | 268d | BCAXBicara Therapeutics | ficerafusp alfa bispecific · oncology | interim_analysis | Watch | — | document | 10-Q: "We expect to achieve substantial enrollment by the end of 2026 to enable an interim analysis in mid-2027 to support potential accelerated approval and U.S. launch in 2028." FORTIFI-HN01 Phase 2/3 (1500mg QW + pembrolizumab, 1L R/M HPV-negative HNSCC). |
| 2027-06-01 → 2027-07-31 | 268d | CABACabaletta Bio | rese-cabtagene autoleucel cell therapy · immunology | topline_results | Watch | — | document | "Cabaletta continues to anticipate reporting data from the registrational, 17-patient dermatomyositis (DM) and antisynthetase syndrome (ASyS) cohort in mid-2027" (14 adult DM, 3 adult ASyS). BLA-enabling topline data. |
| 2027-06-01 → 2027-07-31 | 268d | CBIOCrescent Biopharma | CR-001 bispecific · oncology | topline_results | Watch | — | document | "standard of care chemotherapy combination expansion cohorts of ASCEND ... with initial data anticipated in mid-2027"; also "Phase 2 trial of CR-001 (SKB118) and sac-TMT ... in NSCLC ... initial data expected in mid-2027" (Kelun-Biotech, China). |
| 2027-06-01 → 2027-07-31 | 268d | CCCCC4 Therapeutics | cemsidomide small molecule · hematology | interim_analysis | Watch | — | document | "Data from all cohorts evaluated in the Phase 1b trial are expected in mid-2027" (cemsidomide + elranatamab in RRMM). Company did not call it topline; 75 ug dose declared safe by safety data review committee and trial advancing to 100 ug escalation and 75 ug expansion cohorts. |
| 2027-06-01 → 2027-07-31 | 268d | COAGHemab Therapeutics Holdings | HMB-003 peptide · hematology | interim_analysis | Watch | — | document | 10-Q (Aug 2026): "We expect to initiate first-in-human studies of HMB-003 in the second half of 2026 with initial clinical data in mid-2027." Nov 4, 2026 ASH release reaffirms: Phase 1 (NCT07798505) ongoing, "with initial clinical data expected in mid-2027." Event is the initial clinical data (mid-2027), not the trial start. |
| 2027-06-01 → 2027-07-31 | 268d | CRDLCardiol Therapeutics | CardiolRx small molecule · cardiovascular | topline_results | Watch | — | document | "Topline results are now anticipated in mid-2027, compared with our previous Q1 2027 guidance." Phase III MAVERIC (recurrent pericarditis); timing delayed due to enrollment expansion from 110 to up to 150 patients after blinded review showed fewer recurrences than expected. |
| 2027-06-01 → 2027-07-31 | 268d | DMRADamora Therapeutics | DMR-001 monoclonal antibody · hematology | topline_results | Watch | — | document | "We expect the readout of two proof-of-concept datasets from this trial beginning mid-2027" (10-Q, filed 2026-08-10). Window reflects the start of the two Phase 1/1b PoC readouts; second readout timing not stated, so window is open-ended after mid-2027. |
| 2026-08-11 → 2027-07-31 open | 268d | ELOXEloxx Pharmaceuticals | exaluren small molecule · rare genetic | topline_results | Watch | — | document | "The Company anticipates topline data from the initial 16-week placebo-controlled portion of the study by mid-2027" (Phase 2b in nonsense mutation Alport syndrome, initiated Q3 2026). Window runs from the Aug 11, 2026 guidance date through 2027-07-31. |
| 2027-06-01 → 2027-07-31 | 268d | HRMYHarmony Biosciences Holdings | pitolisant (WAKIX) small molecule · cns | topline_results | Watch | — | document | "WAKIX (pitolisant): Phase 3 trial in PWS (TEMPO) - Topline data expected in mid-2027"; 10-Q: "We anticipate topline data from the TEMPO study in mid-2027." Mid-2027 = Jun-Jul 2027. |
| 2027-06-01 → 2027-07-31 | 268d | HRMYHarmony Biosciences Holdings | EPX-100 small molecule · cns | topline_results | Watch | — | document | Nov 4, 2026 release: "Topline data expected in mid-2027 and anticipated PDUFA date in 2028" for two Global Phase 3 registrational trials in rare epilepsies (LGS LIGHTHOUSE; DS ARGUS). One row covering both trials. Mid-2027 = Jun-Jul 2027 (previously broadened to 1H 2027 from Aug 2026 release). |
| 2027-06-01 → 2027-07-31 | 268d | IDYAIDEAYA Biosciences | darovasertib small molecule · oncology | interim_analysis | Watch | — | document | "IDEAYA plans to provide an update on the OS data as part of the pre-specified interim analysis expected in mid-2027" (OptimUM-02, mUM) |
| 2027-06-01 → 2027-07-31 | 268d | IMMXImmix Biopharma | NXC-201 cell therapy · hematology | topline_results | Watch | — | document | "NEXICART-2 final readout and BLA submission planned mid-2027" (body: "planned in 2027"); mid-2027 window used. |
| 2027-06-01 → 2027-07-31 | 268d | INBXInhibrx Biosciences | INBRX-106 protein · oncology | topline_results | Watch | — | document | "Phase 1/2 study of INBRX-106 in the perioperative setting of non-small cell lung cancer (NSCLC), with initial results targeted by mid-2027." |
| 2027-06-01 → 2027-07-31 | 268d | KLRAKailera Therapeutics | ribupatide injection (KAI-9531) peptide · metabolic | topline_results | Watch | — | document | "Phase 2b high dose clinical trial in obesity fully enrolled with data anticipated mid-2027" (~260 participants in U.S., BMI >=35 without T2D; 10, 13, 16, 20 mg over 48 weeks). Window = mid-2027. |
| 2027-06-01 → 2027-07-31 | 268d | KLRAKailera Therapeutics | KAI-7535 small molecule · metabolic | topline_results | Watch | — | document | "Global Phase 2 trial in obesity fully enrolled with data now anticipated in mid-2027" (safiglipron/KAI-7535, ~300 participants, up to 44 weeks; NCT07497880). Narrowed from full 2027 to mid-2027. |
| 2027-06-01 → 2027-07-31 | 268d | KRSAKorsana Biosciences | KRSA-028 monoclonal antibody · cns | topline_results | Watch | — | document | "Phase 1 healthy volunteer data expected in mid-2027" for KRSA-028 (shuttled anti-amyloid-beta antibody, Alzheimer's). Window per mid-2027 = 2027-06-01..2027-07-31. Reaffirmed in Nov 5, 2026 Q3 release: "Phase 1 healthy volunteer data for KRSA-028 expected mid-2027". |
| 2027-06-01 → 2027-07-31 | 268d | LYELLyell Immunopharma | ronde-cel cell therapy · hematology | topline_results | Watch | — | document | 10-Q: "Pivotal data from the PiNACLE trial are expected in mid-2027" (mid-2027 = Jun-Jul 2027 window). |
| 2027-06-01 → 2027-07-31 | 268d | ORICOric Pharmaceuticals | enozertinib small molecule · oncology | interim_analysis | Watch | — | document | Timeline slide: "Phase 1b Monotherapy, combos w/ amivantamab and w/ chemo Data: Mid-2027" in 1L EGFR exon 20 NSCLC (combo collaboration with J&J). Previous guidance was data in 2H 2026; now mid-2027. Redwood-2 Phase 3 initiation in exon 20 expected after these data. |
| 2027-06-01 → 2027-07-31 | 268d | RCUSArcus Biosciences | AB102 small molecule · immunology | topline_results | Watch | — | document | "A proof-of-concept study evaluating AB102 as a potential oral therapy for patients with chronic spontaneous urticaria is expected in mid-2027." Mid 2027 window; study was expected to start FIH in Aug 2026. |
| 2027-06-01 → 2027-07-31 | 268d | TNXPTonix Pharmaceuticals Holding | TNX-102 SL small molecule · cns | topline_results | Watch | — | document | "Topline data is expected to be reported mid-2027" for the DoD-funded OASIS study of TNX-102 SL in acute stress disorder/reaction; investigator-initiated study conducted by the University of North Carolina. |
| 2027-06-01 → 2027-07-31 | 268d | VRCAVerrica Pharmaceuticals | VP-102 (YCANTH) small molecule · dermatology | topline_results | Watch | — | document | Q2 2026 release: "Topline data from our global Phase 3 program is currently expected in mid-2027, as our studies are recruiting well." 10-Q: "Top-line data from our Program is expected in mid-2027." Program = COVE-2/COVE-3/COVE-4 common warts (US/Japan). |
| 2027-06-01 → 2027-07-31 | 268d | VSTMVerastem | avutometinib + defactinib small molecule · oncology | topline_results | Watch | — | document | Guided milestone: "Report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027." |
| 2027-09-01 → 2027-09-30 | 329d | ALGSAligos Therapeutics | pevifoscorvir sodium small molecule · infectious | topline_results | Core | — | document | "Topline data for both the HBeAg+ and HBeAg- cohorts are expected in late Q3 2027" (Phase 2 B-SUPREME, NCT06963710; enrollment complete: 131 HBeAg+ Part 1a, 114 HBeAg- Part 2a). Reiterated in 10-Q filed 2026-08-06. |
| 2027-07-01 → 2027-09-30 | 329d | ANNXAnnexon | vonaprument monoclonal antibody · ophthalmology | topline_results | Watch | — | document | "final trial completion, including the Month 24 primary endpoint expected in the third quarter of 2027" (ARCHER II dual primary endpoint added). |
| 2027-07-01 → 2027-09-30 | 329d | BCRXBioCryst Pharmaceuticals | navenibart monoclonal antibody · immunology | topline_results | Watch | — | document | "The program remains on track to report top-line results from both doses in Q3 2027"; ALPHA-ORBIT Phase 3 in HAE, enrollment completed June 2026. |
| 2027-07-01 → 2027-09-30 | 329d | JSPRJasper Therapeutics | KP-701 monoclonal antibody · immunology | topline_results | Watch | — | document | 10-Q: "we plan to report first-in-human data in the third quarter of 2027" (KP-701 Phase 1). |
| 2027-04-01 → 2027-09-30 | 329d | PDSBPDS Biotechnology | PDS0301 protein · oncology | topline_results | Watch | — | document | "Q2/Q3-2027 Metastatic castration resistant prostate cancer (Final data readout)" — PDS0301 + docetaxel mCRPC study. |
| 2027-07-01 → 2027-09-30 | 329d | RAPPRapport Therapeutics | RAP-219 small molecule · cns | topline_results | Watch | — | document | "Phase 1 pharmacokinetic data expected in the third quarter of 2027" for an LAI formulation of RAP-219 (Q3 2026 8-K EX-99.1, Nov 4, 2026). |
| 2027-07-01 → 2027-09-30 | 329d | STOKStoke Therapeutics | zorevunersen aso · cns | topline_results | Watch | — | document | Phase 3 EMPEROR (Dravet syndrome) in U.S./UK/Japan, enrollment complete n=162: "A Phase 3 readout is anticipated in the third quarter of 2027." Primary endpoint Week 28 but study remains blinded and all data analyzed at Week 52. Q3 2027 = 2027-07-01..2027-09-30. |
| 2027-07-01 → 2027-09-30 | 329d | TRAXFirst Tracks Biotherapeutics | ANB033 monoclonal antibody · gi hepatology | topline_results | Watch | — | document | Q3 2026 release (Nov 3, 2026): "Top-line data anticipated in Q3 2027" - Phase 1b 50-patient randomized trial of ANB033 vs placebo in eosinophilic esophagitis; reaffirms prior Q3 2027 guidance. |
| 2027-07-01 → 2027-09-30 | 329d | TTRXTurn Therapeutics | GX-03 other · dermatology | topline_results | Watch | — | document | HS Phase 2a: "Q3 2027 Topline Readout Expected" (planned 30 GX-03 : 30 vehicle, 12 weeks). July 2026 deck had guided Q1 2028. First patient dosing planned Q1 2027. |
| 2027-07-01 → 2027-12-31 | 421d | ABSIAbsci | ABS-201 monoclonal antibody · womens health | topline_results | Watch | — | document | Data window per Aug-11 8-K/10-Q: "potential proof-of-concept data in the second half of 2027" after a planned Phase 2 in endometriosis. Sept 24, 2026 release revised initiation: "Anticipated initiation of Phase 2 trial in mid-2027" (previously Q4 2026); no revised data timing stated. |
| 2027-07-01 → 2027-12-31 | 421d | AGENAgenus | botensilimab + balstilimab monoclonal antibody · oncology | interim_analysis | Watch | — | document | "Interim pathologic response data: anticipated in second half of 2027" for the ROBBIN Phase 3 neoadjuvant trial in high-risk Stage II/III MSS colon cancer. |
| 2027-01-01 → 2027-12-31 | 421d | AKTSAktis Oncology | AKY-2519 radiopharma · oncology | interim_analysis | Watch | — | document | "Expect preliminary data from Phase 1b mCRPC clinical trial in 2027." BActinium-1 Phase 1b in PLUVICTO-naive and -experienced mCRPC; only year given. |
| 2027-01-01 → 2027-12-31 | 421d | ALKSAlkermes | ALKS 7290 small molecule · cns | topline_results | Watch | — | document | Phase 2 study in adults with ADHD (NCT07755410, ~312 participants) enrolling; "Data Expected in 2027" per Sept 21, 2026 release headline. |
| 2027-07-01 → 2027-12-31 | 421d | ALTAltimmune | pemvidutide peptide · gi hepatology | topline_results | Watch | — | document | RESTORE Ph2 ALD (48-week study, ~120 patients): "The Company expects to report topline data in the second half of 2027." Enrollment completed July 2026; protocol amended to assess LSM hierarchically at Week 48 then Week 24. |
| 2027-07-01 → 2027-12-31 | 421d | ANROAlto Neuroscience | ALTO-207 small molecule · cns | topline_results | Watch | — | document | "topline data expected in 2H 2027" for PACE-1, the potentially registrational Phase 2b trial of ALTO-207 as adjunctive treatment in TRD (~178 patients, MADRS primary endpoint). Window per 2H 2027 = 2027-07-01..2027-12-31. |
| 2027-01-01 → 2027-12-31 | 421d | ANTXAN2 Therapeutics | epetraborole small molecule · hematology | topline_results | Watch | — | document | Q2 2026 8-K: "The Company anticipates releasing Part 1 data periodically throughout 2027" from the open-label Part 1 of the Phase 2 EBO-PV-201 study in phlebotomy-dependent polycythemia vera; exact timing not stated. |
| 2027-11-01 → 2027-12-31 | 421d | ANTXAN2 Therapeutics | epetraborole small molecule · infectious | topline_results | Watch | — | document | Q2 2026 8-K: "We anticipate reporting topline results in late 2027, subject to enrollment progress." 84-patient investigator-initiated Phase 2 in M. abscessus lung disease; timing is enrollment-dependent. |
| 2027-07-01 → 2027-12-31 | 421d | ARDXArdelyx | tenapanor small molecule · gi hepatology | topline_results | Watch | — | document | Q3 2026 release (2026-11-03): "The Company has completed enrollment ahead of schedule in its Phase 3 clinical trial, ACCEL ... The Company is on track to announce topline data in the second half of 2027." 10-Q confirms enrollment complete. Window = 2H 2027. |
| 2027-10-01 → 2027-12-31 | 421d | ASMBAssembly Biosciences | ABI-6250 small molecule · infectious | interim_analysis | Watch | — | document | "Initial data from the study is expected in the fourth quarter of 2027." Phase 2 (ABI-6250-201) in chronic HDV; first two participants dosed Oct 29, 2026; initial data readout after Week 16 primary endpoint analysis of main cohort. |
| 2027-07-01 → 2027-12-31 | 421d | AURAAura Biosciences | bel-sar other · oncology | topline_results | Watch | — | document | "Topline data from the 15-month primary endpoint remain on track for the second half of 2027, consistent with previously communicated guidance." Phase 3 CoMpass in early choroidal melanoma, fully enrolled (n=108); under SPA with FDA. |
| 2027-01-01 → 2027-12-31 | 421d | AVBPArriVent BioPharma | ARR-217 adc · oncology | interim_analysis | Watch | — | document | "ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg Q3W with further dose optimization data expected in 2027"; CEO quote: "we look forward to dose optimization data expected in 2027." Window per "in 2027". |
| 2027-07-01 → 2027-12-31 | 421d | AVLNAvalyn Pharma | AP01 small molecule · respiratory | topline_results | Watch | — | document | "Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027" (Q2 2026 release, 2026-08-12). 52-week PPF trial; second half of 2027 mapped to 2027-07-01..2027-12-31. |
| 2027-11-01 → 2027-12-31 | 421d | AVLNAvalyn Pharma | AP02 small molecule · respiratory | topline_results | Watch | — | document | AURA Phase 2 (IPF, 12-week, 160 patients): "Topline data are anticipated in late 2027." (Q2 2026 release, 2026-08-12). "late 2027" mapped to 2027-11-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | AXSMAxsome Therapeutics | solriamfetol small molecule · cns | topline_results | Watch | — | document | "The Company anticipates topline results from SUSTAIN in the second half of 2027" (solriamfetol in shift work disorder in adults); same 3Q 2026 update also guides FOCUS-2 (children) and FOCUS-3 (adolescents) ADHD topline results to 2H 2027 for solriamfetol, so those share this window. Narrowed from prior "in 2027" guidance. |
| 2027-07-01 → 2027-12-31 | 421d | AXSMAxsome Therapeutics | AXS-05 small molecule · cns | topline_results | Watch | — | document | "The Company anticipates topline results from the SUMMIT Phase 3 trial in the second half of 2027" - AXS-05 (dextromethorphan-bupropion) in smoking cessation; Phase 3 trial initiated August 2026. |
| 2027-07-01 → 2027-12-31 | 421d | BHVNBiohaven | taldefgrobep alfa protein · metabolic | topline_results | Watch | small impact 55% confidence | document | "As a result of the amended study design, we now anticipate topline data from the monotherapy and combination therapy portions of the trial in 2H 2027" (2H 2027 = 2027-07-01..2027-12-31). Amended to add a GLP-1 combination cohort; supersedes earlier 2H 2026 guidance. |
| 2027-07-01 → 2027-12-31 | 421d | BIOABioAge Labs | BGE-102 small molecule · ophthalmology | topline_results | Watch | — | document | 8-K (Oct 2, 2026): QUELL-DME Phase 2 (oral BGE-102 90 mg, NLRP3 inhibitor) in diabetic macular edema, ~180 participants; "Topline results expected in the second half of 2027". First participant dosed; dosing is not itself a catalyst. Confirms earlier Q2 guidance. |
| 2027-07-01 → 2027-12-31 | 421d | BLSMBlossomHill Therapeutics | BH-30643 small molecule · oncology | interim_analysis | Watch | — | document | "initial Phase 1 data on a chemotherapy combination cohort in the second half of 2027, and updated Phase 1 data on durability of response in TKI-naive patients in the second half of 2027". |
| 2027-04-01 → 2027-12-31 | 421d | BOLTBolt Biotherapeutics | PRA-216 bispecific · immunology | topline_results | Watch | — | document | "Phase 2 development in asthma, COPD, and atopic dermatitis has been initiated, with a Phase 2 study in EoE planned, and with patient data from all four trials expected beginning in the second quarter of 2027 and continuing through the fourth quarter of 2027." Single guided window covers all four Phase 2 trials (asthma, COPD, AD, EoE). |
| 2027-07-01 → 2027-12-31 | 421d | BOLTBolt Biotherapeutics | IL-31 bispecific (Program 2) bispecific · immunology | topline_results | Watch | — | document | "Prana's second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. First-in-human studies in healthy volunteers and patients are expected to begin in the second half of 2027, with clinical data also expected in the second half of 2027." Unnamed program; caveat: same period as study start. |
| 2027-07-01 → 2027-12-31 | 421d | BRVEBraveheart Bio | BHB-1893 small molecule · cardiovascular | interim_analysis | Watch | — | document | "We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027." Phase 3 oHCM trial of BHB-1893 vs metoprolol; first patient dosing guided for 2026 (trial start, not a catalyst). |
| 2027-07-01 → 2027-12-31 | 421d | CBIOCrescent Biopharma | CR-002 adc · oncology | topline_results | Watch | — | document | "Initial data are expected in the second half of 2027" from global Phase 1/2 APOLLO trial of CR-002 (PD-L1 topoisomerase inhibitor ADC), on track to start Q4 2026 after IND allowance. |
| 2027-07-01 → 2027-12-31 | 421d | CCCCC4 Therapeutics | cemsidomide small molecule · hematology | interim_analysis | Watch | — | document | "Enrollment for the Phase 2 MOMENTUM trial is expected to be complete in the first quarter of 2027 with initial investigator-assessed overall response rate data expected in the second half of 2027" (cemsidomide + dexamethasone in RRMM). Company did not call it topline; initial investigator-assessed ORR data. |
| 2027-07-01 → 2027-12-31 | 421d | CGTXCognition Therapeutics | zervimesine small molecule · cns | topline_results | Watch | — | document | Q3 2026 business update: "Top-line results from START are anticipated in the second half of 2027" (Phase 2 START in MCI/early Alzheimer's, with ACTC). Window covers H2 2027; no more precise date given. |
| 2027-01-01 → 2027-12-31 | 421d | CLYMClimb Bio | budoprutug monoclonal antibody · renal | topline_results | Watch | — | document | "additional data from the PrisMN Phase 2 study anticipated in 2027" (pMN; 600 mg/1000 mg cohorts). Enrollment ongoing in 1000 mg cohort. |
| 2026-07-29 → 2027-12-31 open | 421d | CORTCorcept Therapeutics | relacorilant small molecule · oncology | topline_results | Watch | — | document | "BELLA Part B ... Results expected by the end of next year" (platinum-sensitive ovarian cancer post-PARP inhibitor). BELLA Part C, TRIDENT and the Phase 2 relacorilant+enzalutamide prostate cancer trial are also guided to results by the end of next year (8-K 2026-11-03: "will generate important data in 2027"). STELLA (cervical) newly initiated, no results guidance. |
| 2026-07-29 → 2027-12-31 open | 421d | CORTCorcept Therapeutics | nenocorilant small molecule · oncology | topline_results | Watch | — | document | "Our study of nenocorilant with the PD-1 checkpoint inhibitor nivolumab ... will also produce results by the end of next year" (SYNERGY Phase 1b, solid tumors). |
| 2027-01-01 → 2027-12-31 | 421d | DAREDare Bioscience | DARE-HPV small molecule · infectious | topline_results | Watch | — | document | Q2 2026 release: "initiated a Phase 2 study expected to enroll approximately 100 women with persistent high-risk human papillomavirus (HPV) infection. Topline results are expected in 2027." Only year stated, so full-2027 window. |
| 2027-01-01 → 2027-12-31 | 421d | DFTXDefinium Therapeutics | DT120 ODT small molecule · cns | topline_results | Watch | — | document | "Topline data expected in 2027" for Phase 3 Ascend study in MDD. |
| 2027-01-01 → 2027-12-31 | 421d | DNLIDenali Therapeutics | DNL952 (ETV:GAA) protein · rare genetic | topline_results | Watch | — | document | "Dosing of participants with late-onset Pompe disease began in the Phase 1 study of DNL952 in the second quarter of 2026, and initial clinical data are expected in 2027." Year-only window. |
| 2027-01-01 → 2027-12-31 | 421d | DNLIDenali Therapeutics | DNL921 (ATV:Abeta) monoclonal antibody · cns | topline_results | Watch | — | document | "Safety and clinical proof-of-concept data from the ongoing Phase 1/1b study of DNL921 in healthy volunteers and participants with Alzheimer's disease are expected in 2027." Year-only window. |
| 2027-01-01 → 2027-12-31 | 421d | DSGNDesign Therapeutics | DT-818 small molecule · rare genetic | topline_results | Watch | — | document | "Design anticipates reporting data from this trial in 2027" (Phase 1 MAD trial of DT-818 in myotonic dystrophy type 1); reconfirmed 2026-11-04: "Clinical readouts expected in 2027". No narrower window given. |
| 2027-01-01 → 2027-12-31 | 421d | DSGNDesign Therapeutics | DT-168 small molecule · ophthalmology | topline_results | Watch | — | document | "Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers" (Phase 2 biomarker trial in FECD); reconfirmed 2026-11-04: "data expected in 2027". |
| 2027-01-01 → 2027-12-31 | 421d | DTILPrecision BioSciences | PBGENE-DMD gene therapy · rare genetic | topline_results | Watch | — | document | "Initial safety data are targeted for year-end 2026, with efficacy data at distinct timepoints expected to follow in the first and second half of 2027." FUNCTION-DMD Phase 1/2; no specific dates given, so window covers all of 2027. |
| 2027-07-01 → 2027-12-31 | 421d | EDITEditas Medicine | EDIT-401 gene therapy · metabolic | topline_results | Watch | — | document | Part 1 dose-finding topline: "plans to complete enrollment in Part 1 ... with topline safety and efficacy data results available later in 2027." 10-Q: data on at least three patients "by the end of the third quarter of 2027". Exact timing not stated, so H2 2027. |
| 2027-10-01 → 2027-12-31 | 421d | EDSAEdesa Biotech | EB06 monoclonal antibody · dermatology | topline_results | Watch | — | document | Phase 2 double-blind placebo-controlled study of EB06 in up to 80 adults with moderate-to-severe nonsegmental vitiligo (primary endpoint F-VASI change at Week 28): "The Company anticipates that topline data will be available fourth quarter 2027." Fourth quarter 2027 = 2027-10-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | EIKNEikon Therapeutics | EIK1005 small molecule · oncology | interim_analysis | Watch | — | document | "complete results for EIK1005 monotherapy available in the second half of 2027" (company release, 2026-10-23). Second half 2027 = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | EIKNEikon Therapeutics | EIK1004 small molecule · oncology | interim_analysis | Watch | — | document | "Eikon plans to initiate a combination arm of EIK1004-001 evaluating EIK1004 in combination with docetaxel, with plans to report initial results from that combination arm in the second half of 2027." Second half 2027 = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | EIKNEikon Therapeutics | EIK1003 small molecule · oncology | interim_analysis | Watch | — | document | "Eikon is currently enrolling an additional Cohort 1D evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy, for which initial results are expected in the second half of 2027." Second half 2027 = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | EIKNEikon Therapeutics | EIK1001 small molecule · oncology | interim_analysis | Watch | — | document | TeLuRide-008 (Phase 2/3 NSCLC): "Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027." 2H 2027 = 2027-07-01..2027-12-31. |
| 2026-08-11 → 2027-12-31 open | 421d | ELOXEloxx Pharmaceuticals | exaluren small molecule · rare genetic | topline_results | Watch | — | document | "with the final readout by the end of 2027" — final readout of the Phase 2b Alport syndrome study, separate from the initial 16-week topline. "By the end of 2027" window starts at the Aug 11, 2026 document date. |
| 2027-01-01 → 2027-12-31 | 421d | ENTAEnanta Pharmaceuticals | zelicapavir small molecule · infectious | topline_results | Watch | — | document | LOTUS Phase 2b in pediatric RSV: "Dosing began in LOTUS ... with topline data expected in 2027." Document states only the year, so full-year window. |
| 2027-01-01 → 2027-12-31 | 421d | ENTAEnanta Pharmaceuticals | zelicapavir (RESOLVE) small molecule · infectious | topline_results | Watch | — | document | RESOLVE Phase 2b/3 (adults at high risk of severe RSV): "Topline data from the Phase 2b portion of the study are expected in 2027" (release 2026-10-26 announcing first patient dosed). Year-only guidance, full-year window. Drug label includes trial name to distinguish from LOTUS event. |
| 2027-01-01 → 2027-12-31 | 421d | EVMNEvommune | EVO756 small molecule · cns | topline_results | Watch | — | document | Phase 2b migraine prophylaxis trial: "Top-line data expected in 2027" (reiterated in Sept 2026 presentation: "Expect top-line data from Phase 2b migraine trial in 2027"). |
| 2027-10-01 → 2027-12-31 | 421d | EYPTEyePoint | DURAVYU small molecule · ophthalmology | topline_results | Watch | — | document | "DME program remains on track with pivotal Phase 3 topline data from two identical clinical trials anticipated in Q4 2027" (Oct 19, 2026 LUCIA results release); refers to COMO and CAPRI. |
| 2027-07-01 → 2027-12-31 | 421d | FDMT4D Molecular Therapeutics | 4D-150 gene therapy · ophthalmology | topline_results | Watch | — | document | "4FRONT-2 ... topline data expected in H2 2027" (Q2 2026 earnings release). Enrollment completed June 2026. |
| 2027-01-01 → 2027-12-31 | 421d | FTHFaeth Therapeutics | PIKTOR small molecule · oncology | interim_analysis | Watch | — | document | "We look forward to reporting initial safety and efficacy data from PIK-101 in 2027"; first patient dosed April 2026 in Phase 1b/2 HR+/HER2- breast cancer. |
| 2027-07-01 → 2027-12-31 | 421d | GLUEMonte Rosa Therapeutics | MRT-8102 small molecule · immunology | interim_analysis | Watch | — | document | GEMINI-1 Phase 2 in gout: "expected to initiate in Q4 2026 or Q1 2027 ... Initial data are expected in H2 2027." Window H2 2027. |
| 2027-01-01 → 2027-12-31 | 421d | HRMYHarmony Biosciences Holdings | pitolisant HD small molecule · cns | topline_results | Watch | — | document | "Phase 3 registrational clinical trials ongoing in narcolepsy (ONSTRIDE 1) and idiopathic hypersomnia (IH) (ONSTRIDE 2) ... Topline data expected in 2027". Year-only window. |
| 2027-07-01 → 2027-12-31 | 421d | HURATuHURA Biosciences | IFx-2.0 small molecule · oncology | topline_results | Watch | — | document | 10-Q: "We anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 in the second half of 2027." Phase 3 in first-line Merkel cell carcinoma with Keytruda. |
| 2027-07-01 → 2027-12-31 | 421d | IFRXInflaRx | izicopan small molecule · renal | interim_analysis | Watch | — | document | "Initial data from an investigator-initiated open-label pilot study in atypical hemolytic uremic syndrome (aHUS) anticipated in the second half of 2027"; "expected to provide initial select patient data in 2H 2027". |
| 2027-10-01 → 2027-12-31 | 421d | IMAImageneBio | olevaprubart monoclonal antibody · dermatology | topline_results | Watch | — | document | "Topline data from the study is anticipated in the fourth quarter of 2027" (Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis, under amended protocol). 10-Q (same day) repeats "expected in the fourth quarter of 2027". |
| 2027-11-01 → 2027-12-31 | 421d | IMRXImmuneering | atebimetinib (IMM-1-104) small molecule · oncology | interim_analysis | Watch | — | document | Q3 2026 release (Oct 29, 2026): "4Q 2026: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer, with a preliminary data readout expected in late-2027" and "Late-2027: Preliminary data readout expected from Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer." Window = late 2027 (Nov-Dec); preliminary readout, not topline. |
| 2027-01-01 → 2027-12-31 | 421d | IMTXImmatics | IMA402 + IMA401 bispecific · oncology | topline_results | Watch | — | document | "IMA402 in combination with the Company's MAGEA4/8-directed bispecific, IMA401, in lung cancer with first data expected in 2027" - only the year is stated, so full-year window. |
| 2027-01-01 → 2027-12-31 | 421d | IMVTImmunovant | IMVT-1402 monoclonal antibody · immunology | topline_results | Watch | — | document | Graves disease (NCT06727604, NCT07018323) and myasthenia gravis (NCT07039916) potentially registrational trials: "In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG." Rows combined because both share the identical guided window. |
| 2027-07-01 → 2027-12-31 | 421d | IONSIonis Pharmaceuticals | obudanersen aso · cns | topline_results | Watch | — | document | "Obudanersen ... completed enrollment in the Phase 3 REVEAL study, with data anticipated in the second half of 2027". Enrollment completion itself is not a catalyst; readout window only. |
| 2027-07-01 → 2027-12-31 | 421d | IPSCCentury Therapeutics | CNTY-813 cell therapy · metabolic | topline_results | Watch | — | document | "Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated in the second half of 2027" (reaffirmed 2026-10-02). Contingent on IND submission in 4Q 2026. |
| 2026-08-03 → 2027-12-31 open | 421d | IRDOpus Genetics | OPGx-LCA5 gene therapy · rare genetic | topline_results | Watch | — | document | "the Company expects to initiate dosing of OPGx-LCA5 in the fourth quarter of 2026, with topline data expected by the end of 2027." Registrational Phase 3 fully enrolled (8 pts, 6-month run-in); "by the end of 2027" = 2026-08-03..2027-12-31. |
| 2027-01-01 → 2027-12-31 | 421d | IRONDisc Medicine | selcodebart (DISC-0974) monoclonal antibody · gi hepatology | topline_results | Watch | — | document | RALLY-IBD Phase 2 in inflammatory bowel disease: "initial data expected in 2027". |
| 2027-01-01 → 2027-12-31 | 421d | JBIOJade Biosciences | JADE101 monoclonal antibody · renal | interim_analysis | Watch | — | document | "Announced dosing began in JUNIPER, a Phase 2 trial of JADE101 in IgAN... Interim data are expected in 2027." Window per "expected in 2027". |
| 2027-01-01 → 2027-12-31 | 421d | JBIOJade Biosciences | JADE201 monoclonal antibody · immunology | interim_analysis | Watch | — | document | "interim, biomarker-rich data expected in 2027" from the Phase 1 trial of JADE201 in rheumatoid arthritis. Window per "expected in 2027"; no narrower date given. |
| 2027-07-01 → 2027-12-31 | 421d | JBIOJade Biosciences | JADE301 monoclonal antibody · dermatology | interim_analysis | Watch | — | document | "interim data anticipated in the second half of 2027" from the Phase 1 SAD trial of subcutaneous JADE301 in 24 healthy volunteers (trial start Q4 2026). Second half of 2027 per company guidance. |
| 2027-01-01 → 2027-12-31 | 421d | KLRAKailera Therapeutics | KAI-4729 peptide · metabolic | topline_results | Watch | — | document | "IND now active with U.S. FDA; on track to initiate Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026, with data anticipated in 2027." Window = full 2027. |
| 2027-07-01 → 2027-12-31 | 421d | KNSAKiniksa Pharmaceuticals International | KPL-387 monoclonal antibody · cardiovascular | topline_results | Watch | — | document | Q3 2026 release: "Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027." Window = 2H 2027 (Q3/Q4). Trial is event-driven. |
| 2027-07-01 → 2027-12-31 | 421d | KRROKorro Bio | KRRO-121 aso · metabolic | interim_analysis | Watch | — | document | "Dosing of UCD patients is expected to start in the first half of 2027, with an interim clinical readout expected in the second half of 2027" (ANCHOR Part 2, UCD patients). |
| 2027-01-01 → 2027-12-31 | 421d | KRYSKrystal Biotech | KB408 gene therapy · respiratory | interim_analysis | Watch | — | document | "expects to report interim study results in 2027" (SERPENTINE-1 repeat dose Cohort 2B, AATD lung disease, NCT06049082); 10-Q says interim safety and delivery data from Cohort 2B in 2027 |
| 2027-01-01 → 2027-12-31 | 421d | KRYSKrystal Biotech | KB801 gene therapy · ophthalmology | topline_results | Watch | — | document | "The Company now expects to complete enrollment of approximately 60 patients in EMERALD-1 and report top-line results in 2027" (registrational, placebo-controlled, neurotrophic keratitis, NCT06999733); enrollment slower than anticipated. |
| 2027-07-01 → 2027-12-31 | 421d | KURAKura Oncology | darlifarnib small molecule · oncology | topline_results | Watch | — | document | "Complete enrollment in the randomized FIT-001 Phase 1b study evaluating darlifarnib plus cabozantinib in cabozantinib-naive ccRCC in 1H 2027 and report initial clinical data in 2H 2027". Event covers the initial data; enrollment completion not tracked. |
| 2027-07-01 → 2027-12-31 | 421d | LGNDLigand Pharmaceuticals | lasofoxifene small molecule · oncology | topline_results | Watch | — | document | Q3 2026 release: LeonaBio "is on track to complete enrollment of approximately 600 patients in the Phase 3 Elaine-3 clinical trial evaluating lasofoxifene in ER+/HER2-negative, ESR1-mutated metastatic breast cancer in the fourth quarter of 2026 with topline data expected in the second half of 2027." Second half of 2027 = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | LGNDLigand Pharmaceuticals | Qtorin rapamycin small molecule · rare genetic | topline_results | Watch | — | document | Q2 2026 release (2026-08-06): Palvella dosed first patients in LOTU Phase 2 in clinically significant angiokeratomas and "Topline results from the Phase 2 trial are expected in the second half of 2027" = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | LONALeonaBio | lasofoxifene small molecule · oncology | topline_results | Watch | — | document | "remain on track to complete enrollment of ELAINE-3 in the fourth quarter of 2026 with topline data expected in the second half of 2027" (Q2 2026 release, Aug 14 2026). Phase 3 ELAINE-3 (NCT05696626): lasofoxifene + abemaciclib in ER+/HER2- ESR1-mutated mBC; primary endpoint PFS by BICR. Window = second half of 2027 per guidance. |
| 2027-10-01 → 2027-12-31 | 421d | LSTALisata Therapeutics | MAR001 monoclonal antibody · metabolic | topline_results | Watch | — | document | "Both studies are expected to report topline data in the fourth quarter of 2027" (ongoing Phase 2b in sHTG; MAR001/005). CEO quote refers to "next year"; Q4 2027 is the precise stated timing. |
| 2027-10-01 → 2027-12-31 | 421d | LSTALisata Therapeutics | MAR002 monoclonal antibody · rare genetic | topline_results | Watch | — | document | "Both studies are expected to report topline data in the fourth quarter of 2027"; MAR002 described as "Phase 2 proof of concept data in patients with acromegaly next year". Timing stated as Q4 2027; caveat: described elsewhere as "next year". |
| 2027-07-01 → 2027-12-31 | 421d | LTGOLatigo Biotherapeutics | onzotrigine small molecule · pain anesthesia | topline_results | Watch | — | document | "Expect to report topline results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027." 10-Q: placebo-controlled Phase 3 bunionectomy trial and open-label Phase 3 safety trial to initiate 2H 2026, topline expected 2H 2027. Reconfirmed 11/5/2026 Q3 release: "topline results expected in the second half of 2027"; bunionectomy Phase 3 now to add oxycodone/acetaminophen comparator arm and enroll ~480 patients. |
| 2027-07-01 → 2027-12-31 | 421d | LTGOLatigo Biotherapeutics | LTG-321 small molecule · pain anesthesia | topline_results | Watch | — | document | Phase 2 randomized, double-blind, placebo-controlled crossover trial in ~120 knee OA patients: "Expect to report topline results from the Phase 2 clinical trial in the second half of 2027." Enrollment underway at sites in Denmark. Reconfirmed 11/5/2026 Q3 release: "topline results expected in the second half of 2027"; bunionectomy Phase 3 now to add oxycodone/acetaminophen comparator arm and enroll ~480 patients. |
| 2027-07-01 → 2027-12-31 | 421d | LXEOLexeo Therapeutics | LX2006 gene therapy · rare genetic | topline_results | Watch | — | document | "Topline data readout expected in second half of 2027" for SUNRISE-FA 2 pivotal trial in FA cardiomyopathy; reaffirmed 2026-09-22 as on track for 2H 2027. |
| 2027-01-01 → 2027-12-31 | 421d | MAZEMaze Therapeutics | MZE782 small molecule · metabolic | topline_results | Watch | — | document | "Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027". Date not further specified. |
| 2027-11-01 → 2027-12-31 | 421d | MDGLMadrigal Pharmaceuticals | resmetirom small molecule · gi hepatology | topline_results | Watch | — | document | Q3 2026 release (11/3/26): "MAESTRO NASH OUTCOMES on track, data expected late 2027"; forward-looking statements cite "expected receipt of data from the MAESTRO-NASH OUTCOMES trial in late 2027." Narrows prior "in 2027" guidance. F4c compensated cirrhosis, event-driven outcomes trial. |
| 2027-01-01 → 2027-12-31 | 421d | MIRMMirum Pharmaceuticals | MRM-3379 small molecule · cns | topline_results | Watch | — | document | 10-Q: BLOOM Phase 2 study in Fragile-X Syndrome, "expect topline data in 2027." |
| 2027-07-01 → 2027-12-31 | 421d | MIRMMirum Pharmaceuticals | brelovitug monoclonal antibody · infectious | topline_results | Watch | — | document | 8-K: "Topline results from the Phase 3 AZURE-2 and AZURE-3 studies are expected in the second half of 2027." Two separate studies; one row for the guided window. |
| 2027-10-01 → 2027-12-31 | 421d | MLTXMoonLake Immunotherapeutics | sonelokimab bispecific · immunology | topline_results | Watch | — | document | Nov 4, 2026 release milestones: IZAR-2 "Week 52 topline results in Q4 2027" (Phase 3 PsA, TNF-IR population). |
| 2027-07-01 → 2027-12-31 | 421d | MPLTMapLight Therapeutics | ML-007C-MA small molecule · cns | topline_results | Watch | — | document | "Topline results from VISTA are expected in the second half of 2027" (Phase 2 VISTA in Alzheimer's disease psychosis; enrollment ongoing). Also stated in 10-Q filed 2026-08-13. |
| 2027-07-01 → 2027-12-31 | 421d | NERVMinerva Neurosciences | roluperidone small molecule · cns | topline_results | Watch | — | document | Q2 2026 release: "Topline data from Phase A of the trial is expected in the second half of 2027." Phase A = 12-week roluperidone 64 mg vs placebo (N=380 C19 study); primary endpoint Marder NSFS at week 12. |
| 2027-07-01 → 2027-12-31 | 421d | NGNENeurogene | NGN-401 gene therapy · cns | topline_results | Watch | — | document | "We expect to report top-line data in the second half of 2027" from the Embolden registrational trial (1E15 vg dose, females with Rett syndrome); primary analysis after first 24 participants complete 12 months follow-up; no interim data updates planned. |
| 2026-08-03 → 2027-12-31 open | 421d | OBXObsidian Therapeutics | OBX-115 cell therapy · oncology | topline_results | Watch | — | document | "topline data from the melanoma registration-enabling trial, which are expected by year-end 2027"; window starts at release date 2026-08-03 per "by year-end 2027". |
| 2027-07-01 → 2027-12-31 | 421d | ODTXOdyssey Therapeutics | OD-001 small molecule · gi hepatology | topline_results | Watch | — | document | OD-001 topline induction results from two guided trials: randomized placebo-controlled Phase 2b monotherapy and randomized active-controlled Phase 2a combination (OD-001+vedolizumab vs vedolizumab+placebo). "Both studies will be double-blind, with topline induction results expected in the second half of 2027." = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | ODTXOdyssey Therapeutics | OD-002 small molecule · immunology | topline_results | Watch | — | document | Q3 2026 update: OD-002 Phase 1/2a starts H1 2027 in healthy participants; "The Company expects to report healthy participant data in the second half of 2027, including results from an ex vivo stimulation assay." H2 2027 = 2027-07-01..2027-12-31. Patient-cohort efficacy readouts remain guided for H2 2028. |
| 2027-07-01 → 2027-12-31 | 421d | ORKAOruka Therapeutics | ORKA-001 monoclonal antibody · dermatology | interim_analysis | Watch | — | document | "Oruka expects to share 52-week results from EVERLAST-A in December 2026, as well as 52-week results from EVERLAST-B in the second half of 2027." Second half of 2027 = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | PALIPalisade Bio | PALI-2108 small molecule · gi hepatology | topline_results | Watch | — | document | 2026-09-23 Health Canada CTA clearance release: "Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027" (2H 2027 = 2027-07-01..2027-12-31) for Phase 2b ASCENTRA-UC; unchanged from Q2-2026/10-Q guidance. |
| 2027-07-01 → 2027-12-31 | 421d | PCVXVaxcyte | VAX-A1 vaccine · infectious | topline_results | Watch | — | document | 10-Q: "We expect to report topline data from this study in the second half of 2027." (VAX-A1 Phase 1 adult study, Group A Strep.) |
| 2027-10-01 → 2027-12-31 | 421d | PDSBPDS Biotechnology | PDS0301 protein · oncology | topline_results | Watch | — | document | "Q4-2027 Biochemically recurrent prostate cancer (Final data readout)" — final data from PDS0301 + enzalutamide study. |
| 2027-01-01 → 2027-12-31 | 421d | PLRXPliant Therapeutics | PLN-101095 small molecule · oncology | interim_analysis | Watch | — | document | 10-Q Q2 2026: "Enrollment remains strong, progressing ahead of schedule. Interim data is expected in 2027." Refers to FORTIFY Phase 1b indication expansion trial (NSCLC, ccRCC, high TMB) of PLN-101095 +/- pembrolizumab. Only "in 2027" stated; no narrower window given. |
| 2027-07-01 → 2027-12-31 | 421d | PLXProtalix BioTherapeutics Inc. (DE) | PRX-115 protein · metabolic | topline_results | Watch | — | document | Q2 2026 release: "The Company continues to anticipate top-line results in the second half of 2027" for the RELEASE Phase 2 trial of PRX-115 (recombinant PEGylated uricase) in uncontrolled gout. No change to prior guidance. |
| 2027-01-01 → 2027-12-31 | 421d | PRAXPraxis Precision Medicines | elsunersen aso · cns | topline_results | Watch | — | document | 10-Q: "We are currently enrolling EMBRAVE3, a Phase 3 registrational study for early-seizure-onset SCN2A DEE, and expect to announce topline results in 2027." |
| 2027-01-01 → 2027-12-31 | 421d | PRMEPrime Medicine | PM577a gene therapy · rare genetic | topline_results | Watch | — | document | "Prime Medicine has initiated study startup activities, with initial clinical data anticipated in 2027" for the global Phase 1/2 study in Wilson disease (IND cleared July 2026, NZ CTA June 2026). |
| 2027-01-01 → 2027-12-31 | 421d | PRMEPrime Medicine | PM647 gene therapy · rare genetic | topline_results | Watch | — | document | "Prime Medicine expects to submit an IND and/or CTA for PM647 in the third quarter of 2026, with initial clinical data expected in 2027" (AATD). No narrower timing stated. |
| 2027-07-01 → 2027-12-31 | 421d | PVLAPalvella Therapeutics | QTORIN rapamycin small molecule · dermatology | topline_results | Watch | — | document | "Topline results from LOTU are expected in the second half of 2027." Phase 2 trial in clinically significant angiokeratomas; first patients dosed April 2026. |
| 2027-07-01 → 2027-12-31 | 421d | PYXSPyxis Oncology | micvotabart pelidotin (MICVO) + pembrolizumab adc · oncology | interim_analysis | Watch | — | document | "Additional data evaluating initial durability and selection of the recommended Phase 3 dose (RP3D) for the 1L combination are expected in the second half of 2027." |
| 2027-01-01 → 2027-12-31 | 421d | RANIRani Therapeutics Holdings | RT-114 peptide · metabolic | topline_results | Watch | — | document | "The Phase 1b study ... is expected to begin in 2026, with data anticipated in 2027." Window = calendar 2027. Guidance reiterated 2026-10-21 ("Eyes 2027 Obesity Data", MarketBeat/Yahoo) and in Q2 2026 8-K (2026-08-13); no date change. |
| 2027-07-01 → 2027-12-31 | 421d | RAPPRapport Therapeutics | RAP-641 small molecule | topline_results | Watch | — | document | RAP-641 (a6b4 nAChR agonist): IND cleared by FDA; "preliminary results expected in the second half of 2027" (Q3 2026 8-K EX-99.1, Nov 4, 2026). |
| 2027-07-01 → 2027-12-31 | 421d | RNAAtrium Therapeutics | ATR 1072 sirna · rare genetic | topline_results | Watch | — | document | "Initial proof of concept data expected in second half of 2027." Reaffirmed in 11/2/26 8-K ("We now look to the ongoing Phase 1/2 Corventis trial and expect initial proof of concept data in the second half of 2027"), also 10/27/26 8-K (first patient dosed, ~37 pts, PRKAG2 syndrome), 7/14/26 8-K and Q2 10-Q. |
| 2027-07-01 → 2027-12-31 | 421d | RNXTRenovoRx | IAG (intra-arterial gemcitabine via RenovoCath) small molecule · oncology | topline_results | Watch | — | document | "initial topline trial data is expected to be available during the second half of 2027"; trial completion expected 1H 2027 after 86 death events (78 as of Aug 11, 2026). Primary endpoint overall survival; Phase III TIGeR-PaC in LAPC. Earlier Aug 4 release said "mid to late 2027". |
| 2027-07-01 → 2027-12-31 | 421d | RXRXRecursion Pharmaceuticals | REC-4539 small molecule · oncology | interim_analysis | Watch | — | document | "REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27" - window = second half of 2027. |
| 2027-07-01 → 2027-12-31 | 421d | RXRXRecursion Pharmaceuticals | REC-1245 small molecule · oncology | interim_analysis | Watch | — | document | "Preliminary dose expansion data in endometrial cancer are expected in the second half of 2027" (Nov 2, 2026 8-K). Window per "second half of 2027" = 2027-07-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | SABSSAB Biotherapeutics | SAB-142 protein · immunology | topline_results | Watch | — | document | "SAB-142 is currently being evaluated in the registrational Phase 2b SAFEGUARD study ... with enrollment expected to be completed in Q4 2026 and topline data anticipated in 2H 2027." Window per 2H 2027 rule. |
| 2027-07-01 → 2027-12-31 | 421d | SCYXSCYNEXIS | SCY-770 small molecule · renal | interim_analysis | Watch | — | document | 10-Q guidance: "obtaining an early efficacy readout during the second half of 2027" (Phase 2 proof-of-concept study in ADPKD, initiation guided Q4 2026). |
| 2027-07-01 → 2027-12-31 | 421d | SGMTSagimet Biosciences Inc. Series A | denifanstat small molecule · dermatology | topline_results | Watch | — | document | AURORA US Phase 3 in moderate to severe acne (adults and adolescents >=12): "topline results expected in 2H 2027" = 2027-07-01..2027-12-31. First patient dosed Oct 22, 2026 per company release ("Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial"). |
| 2027-07-01 → 2027-12-31 | 421d | SNDXSyndax Pharmaceuticals | revumenib small molecule · hematology | topline_results | Watch | — | document | "Phase 1/2 proof-of-principle trial of revumenib in MF ... expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027." |
| 2027-07-01 → 2027-12-31 | 421d | SRZNSurrozen | SZN-8141 bispecific · ophthalmology | interim_analysis | Watch | — | document | "Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027" (reaffirmed Oct 20, 2026: "initial data expected in the second half of 2027"). Initial data, not stated as topline. |
| 2027-07-01 → 2027-12-31 | 421d | STROSutro Biopharma | STRO-006 adc · oncology | interim_analysis | Watch | — | document | Initial Phase 1 clinical data for ITGB6-targeting ADC STRO-006: "Initial clinical data expected in the second half of 2027" (guidance quoted in the Nov 4, 2026 release's referenced Oct 21, 2026 first-patient-dosed announcement). Note: full Oct 21 release not in workspace; guidance taken from its snippet in this release. |
| 2027-01-01 → 2027-12-31 | 421d | STTKShattuck Labs | SL-846 bispecific · immunology | interim_analysis | Watch | — | document | "we expect ... to share initial Phase 1 clinical data for SL-846 in 2027." Initial Phase 1 data for the dual DR3/IL-23 receptor bispecific; NHP tox data guided for 2H 2026 (preclinical, not recorded). |
| 2027-07-01 → 2027-12-31 | 421d | TRVITrevi Therapeutics | Haduvio (nalbuphine ER) / OCEAN-2 small molecule · respiratory | topline_results | Watch | — | document | Phase 3 OCEAN-2 (IPF-related chronic cough): "plans to initiate the 12-week fixed dosing OCEAN-2 trial, in the third quarter of 2026, with topline results expected in the second half of 2027." Trial initiation is not itself recorded. |
| 2027-07-01 → 2027-12-31 | 421d | TRVITrevi Therapeutics | Haduvio (nalbuphine ER) / LAKE small molecule · respiratory | topline_results | Watch | — | document | Phase 2b LAKE (refractory chronic cough, initiated Q2 2026): "expects to report topline results from the trial in the second half of 2027." SSRE outcome expected earlier (Q4 2026) is recorded separately. |
| 2027-07-01 → 2027-12-31 | 421d | TRVITrevi Therapeutics | Haduvio (nalbuphine ER) / non-IPF ILD Phase 2b small molecule · respiratory | topline_results | Watch | — | document | 10-Q: "We plan to initiate an adaptive design Phase 2b clinical trial ... for non-IPF ILD-related chronic cough in the second half of 2026, subject to a meeting with the FDA ... we would expect topline results from the Phase 2b trial in the second half of 2027." Trial start not yet confirmed. |
| 2027-07-01 → 2027-12-31 | 421d | TVTXTravere Therapeutics | pegtibatinase protein · metabolic | topline_results | Watch | — | document | "Enrollment of pegtibatinase Phase 3 HARMONY Study in HCU continues; Topline data expected in 2H 2027"; body: "with topline data anticipated in 2H 2027" (2H 2027 = 2027-07-01..2027-12-31). Enrollment restarted Q1 2026 after manufacturing-driven pause. |
| 2027-01-01 → 2027-12-31 | 421d | TYRATyra Biosciences | dabogratinib small molecule · oncology | topline_results | Watch | — | document | "SURF303: initial results - 2027"; 10-Q: "initial results expected in 2027" for Phase 2a/b LG-UTUC study (60/80 mg QD). Remains open; only a single-participant observation disclosed 2026-09-09. |
| 2027-07-01 → 2027-12-31 | 421d | UPBUpstream Bio | verekitug monoclonal antibody · respiratory | topline_results | Watch | — | document | "completed enrollment in the VENTURE trial in COPD with 481 participants. Data are expected in the second half of 2027" — Phase 2 VENTURE (NCT06981078); window 2027-07-01..2027-12-31 per "second half of 2027". |
| 2027-07-01 → 2027-12-31 | 421d | UPBUpstream Bio | verekitug monoclonal antibody · respiratory | interim_analysis | Watch | — | document | Phase 2 VALOUR long-term extension (NCT06966479) in severe asthma: "Data from the study are expected in the second half of 2027"; enrollment completed March 2026. Window 2027-07-01..2027-12-31. |
| 2027-10-01 → 2027-12-31 | 421d | VERUVeru | enobosarm small molecule · metabolic | topline_results | Watch | — | document | "Final topline clinical data is expected in the fourth quarter of calendar year 2027." Phase 2b PLATEAU (68-week primary endpoint, % change in total body weight). |
| 2027-01-01 → 2027-12-31 | 421d | VKTXViking Therapeutics | VK2735 peptide · metabolic | topline_results | Watch | — | document | Q3-26 release guidance for VK2735 Phase 3 VANQUISH-1/-2 (SC): "The company expects these studies to be completed in 2027." Also, Part 2 of the maintenance dosing study "results ... to be available in 2027." Both fall in the 2027 window; tracked in one row per natural-key constraint. |
| 2027-07-01 → 2027-12-31 | 421d | VYGRVoyager Therapeutics | VY1706 gene therapy · cns | interim_analysis | Watch | — | document | "H2 2027: Potential for initial biomarker-based data for VY1706, pending enrollment"; 10-Q: initial CSF tau biomarker-based data anticipated in second half of 2027, pending enrollment. |
| 2027-10-01 → 2027-12-31 | 421d | XLOXilio Therapeutics | XTX501 bispecific · oncology | topline_results | Watch | — | document | "Xilio plans to report initial Phase 1 data in patients with metastatic NSCLC in the fourth quarter of 2027." Window narrowed from second half to Q4 2027: 2027-10-01..2027-12-31. |
| 2027-07-01 → 2027-12-31 | 421d | XNCRXencor | XmAb942 monoclonal antibody · immunology | topline_results | Watch | — | document | 2026-10-26 pipeline timeline: "Phase 2b XENITH-UC" ... "Primary endpoint analysis in ~2H27". Approximate 2H2027 window; exact date not stated. |
| 2027-07-01 → 2027-12-31 | 421d | YARWYarrow Bioscience | YB-101 monoclonal antibody · immunology | topline_results | Watch | — | document | Company's Phase 2a/2b GD trial: "Data from the Phase 2a portion of the trial are expected in the second half of 2027." Phase 2a is placebo-controlled proof-of-concept (NCT07682896); 2H 2027 = 2027-07-01..2027-12-31. |
| 2027-01-01 → 2027-12-31 | 421d | ZBIOZenas BioPharma | ZB021 small molecule · dermatology | topline_results | Watch | — | document | "Upon completion and evaluation of the SAD and MAD study, Zenas plans to initiate a proof-of-concept (POC) trial in North America to evaluate clinical activity and safety in psoriasis patients with results anticipated in 2027." Window covers stated "in 2027"; date not narrowed. |
| 2028-01-01 → 2028-03-31 | 512d | ANVSAnnovis Bio | buntanetap small molecule · cns | topline_results | Watch | — | document | Q2 2026 release (Aug 14, 2026): timeline gives database lock for the 6-month analysis in Q1 2027 and "The disease-modifying data readout is expected a year later" -> Q1 2028. 2026-07-09 release states "Q1 2028: 18-month disease-modifying top-line data readout." Phase 3 AD 18-month portion, separate NDA planned. |
| 2028-01-01 → 2028-03-31 | 512d | IRLAIRulya Therapeutics | LAM-001 small molecule · respiratory | topline_results | Watch | — | document | "The Company recently initiated a Phase 2b trial in PH-ILD, and data are anticipated in the first quarter of 2028." Reiterated in Oct 19 2026 corporate presentation (1Q28 PH-ILD Phase 2b data). |
| 2026-09-11 → 2028-03-31 open | 512d | KRSAKorsana Biosciences | KRSA-028 monoclonal antibody · cns | interim_analysis | Watch | — | document | "interim proof-of-concept data evaluating amyloid plaque clearance in Alzheimer's disease patients anticipated by the end of 2027 or the first quarter of 2028." Window spans issue date through Q1 2028. Reaffirmed Nov 5, 2026 Q3 release: "interim proof-of-concept data in Alzheimer's disease patients anticipated by year-end 2027 or first quarter of 2028". |
| 2028-01-01 → 2028-03-31 | 512d | LBRXLB Pharmaceuticals | LB-102 small molecule · cns | topline_results | Watch | — | document | "The Phase 2 ILLUMINATE-1 trial evaluating the efficacy and safety of LB-102 in patients with bipolar 1 depression is enrolling patients, with topline data expected in the first quarter of 2028." |
| 2028-01-01 → 2028-03-31 | 512d | OCULOcular Therapeutix | AXPAXLI small molecule · ophthalmology | topline_results | Watch | — | document | "Following these changes, topline SOL-R results are now expected in the first quarter of 2028" - delayed from prior guidance after protocol amendment adding Week 96 superiority vs aflibercept 8 mg; primary non-inferiority endpoint at Week 56 unchanged. |
| 2028-01-01 → 2028-03-31 | 512d | PALIPalisade Bio | PALI-2108 small molecule · gi hepatology | topline_results | Watch | — | document | 2026-09-22 IND-clearance release: "First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028" for Phase 2 ASCENTRA-CD (~60 patients). Q1 2028 = 2028-01-01..2028-03-31 (earlier 10-Q said "early 2028"). |
| 2028-01-01 → 2028-03-31 | 512d | PHATPhathom Pharmaceuticals | vonoprazan small molecule · gi hepatology | topline_results | Watch | — | document | "Topline results are expected in the first quarter 2028" for registrational Phase 3 pHalcon-NERD-302 (as-needed VOQUEZNA 10 mg in NERD); first subject dosed, sites enrolling across the U.S. |
| 2028-01-01 → 2028-03-31 | 512d | SNDXSyndax Pharmaceuticals | axatilimab + corticosteroids monoclonal antibody · immunology | topline_results | Watch | — | document | "A pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of axatilimab in combination with corticosteroids ... newly diagnosed cGVHD. Topline data are anticipated in early 2028." |
| 2028-01-01 → 2028-03-31 | 512d | XFORX4 Pharmaceuticals | mavorixafor small molecule · hematology | topline_results | Watch | — | document | Oct 29, 2026 investor day presentation: "Topline data expected in Q1 2028" for the pivotal Phase 3 4WARD trial (previously guided as H1 2028 in the Oct 8, 2026 release). Narrowed to Q1 2028 per the newer document. |
| 2026-08-06 → 2028-03-31 open | 512d | ZYMEZymeworks | zanidatamab bispecific · oncology | topline_results | Watch | — | document | "The EmpowHER-303 trial is expected to complete patient enrollment in mid-2027 with top-line data expected by the end of 2027 or early 2028." Wide window per text (end of 2027 through early 2028); enrollment completion itself not recorded as a catalyst. |
| 2028-01-01 → 2028-04-30 | 542d | SPTXSeaport Therapeutics | GlyphAgo small molecule · cns | topline_results | Watch | — | document | "We expect topline data from this Phase 2a trial in early 2028." Phase 2a proof-of-pharmacology trial in GAD patients with sleep disturbance; first patient dosed (Oct 7, 2026); timing reaffirmed in Q3 2026 release, Nov 2, 2026. |
| 2028-01-01 → 2028-06-30 | 603d | BDTXBlack Diamond Therapeutics | silevertinib small molecule · oncology | interim_analysis | Watch | — | document | 10-Q: Phase 2 silevertinib+temozolomide in newly diagnosed EGFRvIII+ MGMT-unmethylated GBM has "an interim PFS analysis anticipated in the first half of 2028." Randomized portion initiation Q4 2026 not recorded (trial start). |
| 2028-01-01 → 2028-06-30 | 603d | CRBPCorbus Pharmaceuticals Holdings | CRB-701 adc · oncology | interim_analysis | Watch | — | document | "Interim ORR readout in 2L OPSCC - 1H 2028" per Oct 15, 2026 corporate presentation milestones for TEMPO-1. |
| 2028-06-01 → 2028-06-30 | 603d | CTNMContineum Therapeutics | PIPE-791 small molecule · respiratory | topline_results | Core | — | document | 10-Q: "Based on enrollment to date at our clinical sites, we believe we remain on track to complete the PROPEL-IPF clinical trial in June 2028." Phase 2 PROPEL-IPF (NCT07284459), ~324 IPF patients, 26 weeks; window reflects stated month only — topline timing after completion is not separately disclosed. |
| 2028-01-01 → 2028-06-30 | 603d | DNLIDenali Therapeutics | tividenofusp alfa-eknm (AVLAYAH) protein · rare genetic | topline_results | Watch | — | document | "Denali also completed enrollment of Cohort B, for a total enrollment of 65 participants across Cohorts A and B, in the global Phase 2/3 COMPASS study... Data from the COMPASS study are expected in the first half of 2028." Confirmatory study in MPS II (Hunter syndrome). |
| 2028-04-01 → 2028-06-30 | 603d | PDSBPDS Biotechnology | PDS0301 protein · oncology | interim_analysis | Watch | — | document | "Q2-2028 Phase 3 – Colorectal cancer with liver metastases (Interim data readout)" — registrational Phase 3 protocol still in design as of Oct 2026. |
| 2028-01-01 → 2028-06-30 | 603d | STTKShattuck Labs | SL-325 monoclonal antibody · immunology | topline_results | Watch | — | document | "Data from the induction portion of the trial are expected in the first half of 2028." RECEPTIVE-CD1 Phase 2b in Crohn's disease, expected to initiate Q3 2026; primary endpoint endoscopic response at 12 weeks. |
| 2028-01-01 → 2028-06-30 | 603d | TRVITrevi Therapeutics | Haduvio (nalbuphine ER) / OCEAN-1 small molecule · respiratory | topline_results | Watch | — | document | Phase 3 OCEAN-1 (IPF-related chronic cough, 52-wk fixed dosing, initiated Q2 2026): "Topline data from the 52-week fixed dosing OCEAN-1 trial is expected in the first half of 2028." Same in 10-Q. |
| 2028-01-01 → 2028-06-30 | 603d | TTRXTurn Therapeutics | GX-03 other · infectious | interim_analysis | Watch | — | document | Planned Phase 3 onychomycosis trial: "1H 2028 Interim Analysis Expected" (Week 26 interim, N~250, primary complete cure at Week 52). Phase 3 first patient dosing planned Q1 2027. |
| 2028-01-01 → 2028-06-30 | 603d | XFORX4 Pharmaceuticals | mavorixafor small molecule · hematology | topline_results | Watch | — | document | Oct 29, 2026 investor day presentation / pipeline slide: 4STEPS Phase 2b (G-CSF dose reduction) "Topline data H1 2028"; trial initiation guided for Q1 2027. |
| 2028-06-01 → 2028-07-31 | 634d | ALLOAllogene Therapeutics | cema-cel cell therapy · oncology | topline_results | Watch | — | document | "We anticipate ... conducting the primary EFS analysis in mid-2028" for ALPHA3; window = mid 2028. |
| 2028-06-01 → 2028-07-31 | 634d | IKTInhibikase Therapeutics | IKT-001 small molecule · cardiovascular | topline_results | Watch | — | document | Corporate overview: "Mid 2028 Unblinded Data (PVR reduction) readout for Part A of Phase 3 IMPROVE-PAH Study (n=120)"; "Mid 2028 - Part A - PVR Efficacy Data". |
| 2028-06-01 → 2028-07-31 | 634d | IMRXImmuneering | atebimetinib (IMM-1-104) small molecule · oncology | topline_results | Watch | — | document | Q3 2026 release (Oct 29, 2026): "Mid-2028: Topline data readout from the MAPKeeper 301 trial"; enrollment ahead of schedule (target expanding 510 to 570 patients) with "potential to accelerate current mid-2028 topline data guidance." Window unchanged = mid 2028 (Jun-Jul). |
| 2028-06-01 → 2028-07-31 | 634d | KLRAKailera Therapeutics | ribupatide injection (KAI-9531) peptide · metabolic | topline_results | Watch | — | document | "KaiNETIC Global Phase 3 program in obesity fully enrolled with data anticipated mid-2028" (3 trials, ~5,000 participants, up to 10 mg weekly over 76 weeks). Narrowed from 2028 to mid-2028. |
| 2028-06-01 → 2028-07-31 | 634d | NKTRNektar Therapeutics | rezpegaldesleukin protein · dermatology | topline_results | Watch | — | document | "cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028" (Q2 2026 earnings release, Aug 13, 2026). Company-guided initial Phase 3 (ZENITH AD) data readouts; no specific trial/date given. |
| 2028-06-01 → 2028-07-31 | 634d | PRQRProQR Therapeutics | — aso · gi hepatology | interim_analysis | Watch | — | document | NTCP franchise: potentially registration-enabling Phase 2 program "expected to start in mid-2027 with first interim analysis data expected by mid-2028", subject to regulatory interactions. |
| 2028-07-01 → 2028-12-31 | 787d | DNTHDianthus Therapeutics | claseprubart monoclonal antibody · immunology | topline_results | Watch | — | document | "We expect to report top-line results from this trial in the second half of 2028" (Phase 3 EMERGE registrational trial in gMG, initiated June 2026). |
| 2028-07-01 → 2028-12-31 | 787d | ENTXEntera Bio | EB613 peptide · metabolic | topline_results | Watch | — | document | "Entera plans to initiate the registrational Phase 3 study in late 2026, with topline results anticipated in the second half of 2028." (12-month Phase 3, ~750 postmenopausal women, total hip BMD primary endpoint). |
| 2028-01-01 → 2028-12-31 | 787d | EVMNEvommune | EVO301 protein · dermatology | topline_results | Watch | — | document | Pipeline slide: EVO301 (IL-18BP) atopic dermatitis "Phase 2b Data Anticipated 2028"; Phase 2b trial planned to start mid-2027, so readout year only. |
| 2028-01-01 → 2028-12-31 | 787d | IFRXInflaRx | izicopan small molecule · immunology | topline_results | Watch | — | document | "intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028" - randomized, double-blind, placebo-controlled Phase 2 in AAV with renal involvement (site initiation early 2027; key readouts at 24 weeks). Open-label GC-replacement Phase 2 first data also guided to 2028. Year-level window only. |
| 2028-01-01 → 2028-12-31 | 787d | IFRXInflaRx | izicopan small molecule · renal | interim_analysis | Watch | — | document | "InflaRx planning pilot study in IgA nephropathy (IgAN) to be initiated in 2027, with expected early data readout in 2028" (includes rapidly progressive IgAN/RPGN); year-level window only. |
| 2028-01-01 → 2028-12-31 | 787d | IMAImageneBio | olevaprubart monoclonal antibody · dermatology | topline_results | Watch | — | document | "Initial data expected in 2028" from the Phase 2 alopecia areata study, which the company plans to initiate in 2026. Only a year is given; window spans 2028. |
| 2028-01-01 → 2028-12-31 | 787d | IMVTImmunovant | IMVT-1402 monoclonal antibody · cns | topline_results | Watch | — | document | CIDP (NCT07032662) and Sjogren's disease (NCT06979531) potentially registrational trials: "Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD". Rows combined (identical guided window; CIDP neurological, SjD immunology). |
| 2028-10-01 → 2028-12-31 | 787d | IRLAIRulya Therapeutics | LAM-001 small molecule · respiratory | topline_results | Watch | — | document | "The Company plans to initiate a Phase 2 study in SAPH in 4Q26, with data anticipated in the fourth quarter of 2028." Trial start itself not recorded; reiterated in Oct 19 2026 presentation (4Q28 SAPH Phase 2 data). |
| 2028-01-01 → 2028-12-31 | 787d | KURAKura Oncology | ziftomenib small molecule · oncology | topline_results | Watch | — | document | 10-Q: "we anticipate topline results from the MRD-negative CR accelerated endpoint in the intensive chemotherapy setting in 2028" (KOMET-017-IC). Year-level guidance only. |
| 2028-01-01 → 2028-12-31 | 787d | MDGLMadrigal Pharmaceuticals | resmetirom small molecule · gi hepatology | topline_results | Watch | — | document | Q3 2026 10-Q (11/3/26): MAESTRO-NASH remains ongoing generating confirmatory outcomes data to 54-months that, if positive, is expected to verify a clinical benefit and support full FDA approval; "We expect outcomes data from MAESTRO-NASH in 2028." Full-approval risk window. |
| 2028-01-01 → 2028-12-31 | 787d | MPLTMapLight Therapeutics | ML-007C-MA small molecule · cns | topline_results | Watch | — | document | Planned registrational Phase 3 ZEPHYR-2 in schizophrenia: Company "plans to engage with the FDA at an End-of-Phase 2 meeting ... including the planned Phase 3 ZEPHYR-2 trial, with topline results expected in 2028". Subject to FDA feedback at EOP2. |
| 2028-07-01 → 2028-12-31 | 787d | NERVMinerva Neurosciences | roluperidone small molecule · cns | topline_results | Watch | — | document | Q2 2026 release: "Topline data from Phase B of the trial is expected in the second half of 2028." Phase B = 52-week double-dummy relapse assessment vs risperidone/aripiprazole/olanzapine. |
| 2028-01-01 → 2028-12-31 | 787d | OCGNOcugen | OCU410 gene therapy · ophthalmology | topline_results | Watch | — | document | "2028 Phase 3 topline data; BLA submission" for OCU410 in geographic atrophy; Phase 3 (ArMaDa, n~237) initiated 3Q 2026, first patient dosed. |
| 2028-07-01 → 2028-12-31 | 787d | ODTXOdyssey Therapeutics | OD-002 small molecule · immunology | topline_results | Watch | — | document | Company-guided: "Phase 1/2a Trial Initiation Expected in H1 2027 With Efficacy Readouts Expected in H2 2028" (OD-002, oral SLC15A4 inhibitor; Phase 1 healthy volunteers then Phase 2a basket cohorts incl. cutaneous lupus erythematosus). "Second half of 2028" = 2028-07-01..2028-12-31. Timeline from Sept 2026 corporate deck; readout window only, no specific data date. |
| 2026-08-03 → 2028-12-31 open | 787d | SPTXSeaport Therapeutics | GlyphAgo small molecule · cns | topline_results | Watch | — | document | "We expect to initiate a Phase 2/3 trial ... in the first half of 2027, with topline data expected by the end of 2028." Randomized, double-blind, placebo-controlled GAD trial; not yet initiated (reaffirmed in Q3 2026 release, Nov 2, 2026). |
| 2028-01-01 → 2028-12-31 | 787d | TARSTarsus Pharmaceuticals | IRX-101 small molecule · ophthalmology | topline_results | Watch | — | document | Q3 2026 release (2026-11-03): "Plan to initiate the Phase 3 Comfort study ... in the first half of 2027, with topline results expected in 2028." Year only = 2028-01-01..2028-12-31. Trial not yet started; company guidance. |
| 2028-10-01 → 2028-12-31 | 787d | TTRXTurn Therapeutics | GX-03 other · infectious | topline_results | Watch | — | document | Planned Phase 3 onychomycosis trial: "Q4 2028 Topline Results Expected"; primary endpoint complete cure at Week 52, BID topical, N~250. |
| 2028-11-01 → 2028-12-31 | 787d | XERSXeris Biopharma Holdings | XP-8121 small molecule · metabolic | topline_results | Watch | — | document | "Cornerstone trial expected to initiate by year-end, ... data expected late 2028"; "expected timing of topline results in late 2028" for the Phase 3 Cornerstone study in hypothyroidism (500 patients, TSH primary endpoint). Guided window = Nov-Dec 2028. |
| 2029-01-01 → 2029-06-30 | 968d | ELOXEloxx Pharmaceuticals | exaluren small molecule · rare genetic | topline_results | Watch | — | document | EXPRESS Phase 2 in nonsense-mutation ADPKD (design finalized per Oct 20, 2026 PR; disclosed in 8-K item 8.01): "First patient dosing is expected in the third quarter of 2027, with topline data expected in the first half of 2029." Supersedes Aug 2026 guidance of ADPKD topline "by mid-2028". |
| 2029-06-01 → 2029-07-31 | 999d | IKTInhibikase Therapeutics | IKT-001 small molecule · cardiovascular | topline_results | Watch | — | document | Corporate overview: "Mid 2029 Topline 6MWD readout from Part B of Phase 3 IMPROVE-PAH Study (n=300)"; "Mid 2029 - Part B - 6MWD Efficacy". |
| 2029-07-01 → 2029-12-31 | 1152d | AGENAgenus | botensilimab + balstilimab monoclonal antibody · oncology | interim_analysis | Watch | — | document | "Interim analysis of EFS: anticipated in second half of 2029" (ROBBIN Phase 3). |
| 2029-01-01 → 2029-12-31 | 1152d | ALTAltimmune | pemvidutide peptide · gi hepatology | topline_results | Watch | — | document | PERFORMA Ph3 MASH: "The 52-week data readout from the PERFORMA trial to support the accelerated approval of pemvidutide is anticipated in 2029." Trial enrolling since Aug 2026; final liver-event outcome data ~60 months. |
| 2029-01-01 → 2029-12-31 | 1152d | PBLSParabilis Medicines | zolucatetide peptide · oncology | topline_results | Watch | — | document | PEDESTAL Phase 3 registrational trial in desmoid tumors: "initiation planned in the first half of 2027 and topline results anticipated in 2029." Year-only guidance => 2029-01-01..2029-12-31. |
| 2029-07-01 → 2029-12-31 | 1152d | PROKProKidney | rilparencel cell therapy · renal | topline_results | Watch | — | document | PROACT 1 confirmatory composite time-to-event analysis topline: "anticipate topline data readout of the confirmatory endpoint (composite time-to-event) in the second half of 2029"; full enrollment ~470 patients expected 2H 2026. |
| 2029-01-01 → 2029-12-31 | 1152d | TARSTarsus Pharmaceuticals | gildeuretinol small molecule · rare genetic | topline_results | Watch | — | document | NORTHSTAR Phase 3 (Stargardt disease, ALK-001, acquired with Alkeus): "currently being evaluated in the global NORTHSTAR Phase 3 trial, with topline data anticipated in 2029." Year only = 2029-01-01..2029-12-31. Reaffirmed in Q3 2026 release (2026-11-03). |
| 2030-07-01 → 2030-12-31 | 1517d | AGENAgenus | botensilimab + balstilimab monoclonal antibody · oncology | topline_results | Watch | — | document | "Final analysis of EFS: anticipated in second half of 2030" (ROBBIN Phase 3). |
| 2030-01-01 → 2030-12-31 | 1517d | REPLReplimune Group | RP1 (vusolimogene oderparepvec) gene therapy · oncology | topline_results | Watch | — | document | IGNYTE-3 confirmatory Phase 3 (OS primary endpoint): "The primary endpoint, expected to readout in 2030, is overall survival." Year only; widened to full year 2030. |
| 2030-01-01 → 2032-12-31 | 2248d | MDGLMadrigal Pharmaceuticals | resmetirom small molecule · gi hepatology | topline_results | Watch | — | document | Q3 2026 10-Q (11/3/26): new Phase 3 MAESTRO-CSPH outcomes trial in F4c with CSPH enrichment (n>2,000); "we expect to initiate MAESTRO-CSPH in the first half of 2027 and anticipate results in the early 2030s." Wide window; dependent on regulatory discussions. |